<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1810222748
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        IRINOTECAN JAZEERA 20 mg/ml concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRINOTECAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        concentrate for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        98.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="THYMOORGAN PHARMAZIE GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            THYMOORGAN PHARMAZIE GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Irinotecan Jazeera is an anticancer medicine containing the active substance irinotecan hydrochloride, trihydrate.</p><p>&nbsp;</p><p>Irinotecan hydrochloride trihydrate interferes with the growth and spread of cancer cells in the body.</p><p>&nbsp;</p><p>Irinotecan Jazeera is indicated in combination with other medicines for the treatment of patients with advanced or metastatic cancer of the colon or rectum.</p><p>&nbsp;</p><p>Irinotecan Jazeera may be used alone in patients with metastatic cancer of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Irinotecan Jazeera</strong></p><ul><li>&nbsp; &nbsp; If you have chronic inflammatory bowel disease and/or bowel obstruction</li><li>&nbsp; &nbsp; If you are allergic to irinotecan hydrochloride trihydrate or any of the other ingredients of this medicine (listed in section 6)</li><li>&nbsp; &nbsp; If you are a breast-feeding woman (see section 2)</li><li>&nbsp; &nbsp; If your bilirubin level is higher than 3 times the upper limit of the normal range</li><li>&nbsp; &nbsp; If you have severe bone marrow failure</li><li>&nbsp; &nbsp; If you are in poor general condition (WHO performance status higher than 2)</li><li>&nbsp; &nbsp; If you are taking or have recently taken St John&rsquo;s Wort (a herbal extract containing Hypericum)</li><li>&nbsp; &nbsp; If you are to take or have recently taken live attenuated vaccines (vaccines against yellow fever, chicken pox, shingles, measles, mumps, rubella, tuberculosis, rotavirus, influenza) and during the 6 months after stopping chemotherapy</li></ul><p>If you receive Irinotecan Jazeera in combination with other medicines, please make sure that you also read the package leaflet of the other medicines regarding additional contraindications.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using Irinotecan Jazeera.</p><ul><li>&nbsp; &nbsp; If you have Gilbert&rsquo;s syndrome, an inherited condition that can cause elevated bilirubin levels and jaundice (yellow skin and eyes)</li></ul><p>&nbsp;</p><p>Take special care with Irinotecan Jazeera. The use of Irinotecan Jazeera should be confined to units specialised in the administration of cytotoxic chemotherapy and it should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.</p><p>&nbsp;</p><p><em>Diarrhoea </em></p><p>Irinotecan can cause diarrhoea, which in some cases may be severe. This may start a few hours or a couple of days after the medicine infusion. If left untreated, it could lead to dehydration and serious chemical imbalances, which can be life threatening. Your doctor will prescribe medicine to help prevent or control this side effect. Make sure you get the medicine right away, so that you will have it at home when you need it.</p><ul><li>&nbsp; &nbsp; Take the medicine as prescribed at the first sign of loose or frequent bowel movements.</li><li>&nbsp; &nbsp; Drink large amounts of water and (or) salty drinks (fizzy water, soda or soup).</li><li>&nbsp; &nbsp; Call your doctor or nurse if you still have diarrhoea, especially if it lasts more than 24 hours, or if you get lightheaded, dizzy, or faint.</li></ul><p>&nbsp;</p><p><em>Neutropenia (decrease in some white blood cells) </em></p><p>This medicine can lower your white blood cell count, mainly in the weeks after the medicine is given. This can increase the risk of getting an infection. Be sure to let your doctor or nurse know right away if you have any signs of infection, such as fever (38&deg;C or higher), chills, pain when passing urine, a new cough, or bringing up sputum. Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.</p><p>&nbsp;</p><p><em>Blood monitoring </em></p><p>Your doctor will likely test your blood before and during your treatment, to check for effects of the medicine on blood counts or on blood chemistry. Based on the test results, you may need medicines to help treat the effects. Your doctor may also need to reduce or delay your next dose of this medicine, or even stop it altogether. Keep all your appointments for doctor visits and lab tests.</p><p>&nbsp;</p><p>This medicine may lower your platelet count in the weeks after it is given, which can increase your risk of bleeding. Speak with your doctor before taking any medicines or supplements that might affect your body&rsquo;s ability to stop bleeding, such as aspirin or aspirin-containing medicines, warfarin, or vitamin E. Tell your doctor right away if you have unusual bruising, or bleeding such as nosebleeds, bleeding gums when you brush your teeth, or black, tarry stools.</p><p>&nbsp;</p><p><em>Nausea and vomiting </em></p><p>You may have nausea and vomiting on the day you receive this medicine or in the first few days after. Your doctor may give you medicine before your treatment to help prevent nausea and vomiting. Your doctor will likely prescribe anti-nausea medicines that you can take at home. Have these medicines on hand for when you need them. Call your doctor if you are unable to take fluids by mouth due to nausea and vomiting.</p><p>&nbsp;</p><p><em>Acute cholinergic syndrome </em></p><p>This medicine may affect part of your nervous system that controls body secretions, leading to what is known as cholinergic syndrome. Symptoms can include runny nose, increased saliva, excess tears in the eyes, sweating, flushing, abdominal cramps, and diarrhoea. Let your doctor or nurse know right away if you notice any of these symptoms, as there are medicines that can help control them.</p><p>&nbsp;</p><p><em>Lung disorders </em></p><p>Rarely, people on this medicine have serious lung problems, Tell your doctor right away if you have new or worsening cough, trouble breathing, and fever. Your doctor may need to stop your treatment to manage this problem.</p><p>&nbsp;</p><p>This medicine may increase your risk of major blood clots in the veins of the legs or lungs, which can travel to other parts of the body such as the lungs or brain. Tell your doctor right away if you notice chest pain, shortness of breath, or swelling, pain, redness, or warmth in an arm or leg.</p><p>&nbsp;</p><p><em>Chronic intestinal inflammation and/or intestinal blockage </em></p><p>Call your doctor if you have pain in your belly and you cannot move your bowels, especially if you also have bloating and loss of appetite.</p><p>&nbsp;</p><p><em>Irradiation therapy </em></p><p>If you recently received treatment with pelvic or abdominal radiotherapy, you may be at increased risk of developing bone marrow suppression. Please talk to your doctor before starting Irinotecan Jazeera.</p><p>&nbsp;</p><p><em>Kidney function </em></p><p>Occurrences of kidney dysfunction have been reported.</p><p>&nbsp;</p><p><em>Cardiac disorders </em></p><p>Inform your doctor if you suffer/suffered from heart disease or if you previously received anticancer medicines. Your doctor will monitor you closely and discuss with you how risk factors (for example smoking, high blood pressure and to high fat content) can be reduced.</p><p>&nbsp;</p><p><em>Vascular disorders </em></p><p>Irinotecan is rarely associated with blood flow disorders (blood clots in the vessels of your legs and lungs) and it may occur rarely in patients with multiple risks factors.</p><p>&nbsp;</p><p><em>Others </em></p><p>This medicine may cause sores in the mouth or on the lips, often within the first few weeks after starting treatment. This can cause mouth pain, bleeding, or even trouble eating. Your doctor or nurse can suggest ways to reduce this, such as changing the way you eat or how you brush your teeth. If needed, your doctor can prescribe medicine to help with the pain.</p><p>&nbsp;</p><p>For contraception and breast-feeding information, refer to the information provided below under section Contraception, pregnancy, breast-feeding and fertility.</p><p>&nbsp;</p><p>Tell your doctor or dentist that you are on this medicine if you are planning to have surgery or any procedure.</p><p>&nbsp;</p><p>If used in combination with other anticancer medicines for your condition please make sure that you also read the leaflets for the other medicine.</p><p>&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Irinotecan Jazeera</strong></p><p>Irinotecan Jazeera can interact with a number of medicines and supplements, which may either raise or lower the level of the medicine in your blood. Tell your doctor or pharmacist if you are using, have recently used or might use any of the following:</p><ul><li>&nbsp; &nbsp; Medicines used to treat seizure (carbamazepine, phenobarbital, phenytoin and fosphenytoin)</li><li>&nbsp; &nbsp; Medicines used to treat fungal infection (ketoconazole, itraconazole, voriconazole and posaconazole)</li><li>&nbsp; &nbsp; Medicines used to treat bacterial infection (clarithromycine, erythromycin and telithromycine)</li><li>&nbsp; &nbsp; Medicines used to treat tuberculosis (rifampicin and rifabutin)</li><li>&nbsp; &nbsp; St. John&#39;s Wort (a herbal dietary supplement)</li><li>&nbsp; &nbsp; Live attenuated vaccines</li><li>&nbsp; &nbsp; Medicines used to treat HIV (indinavir, ritonavir, amprenavir, fosamprenavir, nelfinavir, atazanavir, and others)</li><li>&nbsp; &nbsp; Medicines used to suppress your body&rsquo;s immune system to prevent transplant rejection (cyclosporine and tacrolimus)</li><li>&nbsp; &nbsp; Medicines used to treat cancer (regorafenib, crizotinib, idelalisib and apalutamide)</li><li>&nbsp; &nbsp; Vitamin K antagonists (common blood thinner such as Warfarin)</li><li>&nbsp; &nbsp; Medicines used to relax muscles used during general anaesthesia and surgery (suxamethonium)</li><li>&nbsp; &nbsp; 5-fluorouracil/folinic acid</li><li>&nbsp; &nbsp; Bevacizumab (a blood vessel growth inhibitor)</li><li>&nbsp; &nbsp; Cetuximab (an EGF receptor inhibitor)</li></ul><p>Tell your doctor, pharmacist or nurse before being given Irinotecan Jazeera<strong> </strong>if you are already having, or have recently had chemotherapy (and radiotherapy).</p><p>&nbsp;</p><p>Don&#39;t start or stop taking any medicines while you are on Irinotecan Jazeera without talking with your doctor first.</p><p>&nbsp;</p><p>This medicine can cause serious diarrhoea. Try to avoid laxatives and stool softeners while taking this medicine.</p><p>&nbsp;</p><p>There may be more medicines that interact with Irinotecan Jazeera. Check with your doctor, pharmacist or nurse about your other medicines, herbs, and supplements, and whether alcohol can cause problems with this medicine.</p><p>&nbsp;</p><p><strong>Contraception, pregnancy, breast-feeding and fertility</strong></p><p><em>Contraception </em></p><p>If you are a woman of childbearing age, then you have to use effective contraception during and up to 6 months after stopping treatment.</p><p>&nbsp;</p><p>As a man, you have to use effective contraception during and up to 3 months after stopping treatment. It is important to check with your doctor about what kinds of birth control can be used with this medicine.</p><p>&nbsp;</p><p><em>Pregnancy </em></p><p>This medicine may cause problems with the foetus if taken at the time of conception or during pregnancy. Before initiating treatment, your doctor will ensure that you are not pregnant.</p><p>&nbsp;</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><em>Breast-feeding </em></p><p>Irinotecan and its metabolite were measured in human milk. Breast-feeding should be discontinued for the duration of your treatment with this medicine.</p><p>&nbsp;</p><p>If you are breast-feeding, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><em>Fertility </em></p><p>No studies have been done, nevertheless, this medicine may affect fertility. Prior to taking this medicine talk with your doctor about the possible risk with this medicine and the options that may preserve your ability to have children.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You may notice that you are dizzy and/or have trouble with your vision in the first 24 hours or so after you take this medicine. Do not drive or operate machinery if you have this side effect.</p><p>&nbsp;</p><p><strong>Irinotecan Jazeera</strong><strong> </strong><strong>contains sorbitol and sodium</strong></p><p>Irinotecan Jazeera<strong> </strong>contains sorbitol. Each vial of Irinotecan Jazeera 40 mg/2 ml and 100 mg/5 ml Concentrate for Solution for Infusion contains 90 mg or 225 mg sorbitol; respectively. Sorbitol is a source of fructose. If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects.</p><p>&nbsp;</p><p>You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.</p><p>&nbsp;</p><p>Irinotecan Jazeera contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>Irinotecan Jazeera will be given to you by healthcare professionals.</p><p>&nbsp;</p><p>Your doctor may recommend a DNA test before your first dose of Irinotecan Jazeera.</p><p>&nbsp;</p><p>Some people are genetically more likely to have certain side effects from the medicine.</p><p>&nbsp;</p><p>The amount of Irinotecan Jazeera that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.</p><p>&nbsp;</p><p>Irinotecan Jazeera is injected into a vein through an intravenous route (IV). You will receive this injection in a clinic or hospital setting. Irinotecan Jazeera must be given slowly, and the IV infusion can take up to 90 minutes to complete.</p><p>&nbsp;</p><p>You may be given other medications to prevent nausea, vomiting, diarrhoea, and other side effects while you are receiving Irinotecan Jazeera. You may need to keep using these medicines for at least a day after your Irinotecan Jazeera injection.</p><p>&nbsp;</p><p>Tell your care givers if you feel any burning, pain, or swelling around the IV needle when Irinotecan Jazeera is injected. If the medicine escapes from the vein it can cause tissue damage. If you experience pain or notice redness or swelling at the IV site while you are receiving Irinotecan Jazeera, alert your healthcare professional immediately.</p><p>&nbsp;</p><p>There are currently several treatment schedules recommended for Irinotecan Jazeera. It is usually given either once every 3 weeks (Irinotecan Jazeera given alone) or once every 2 weeks (Irinotecan Jazeera given in combination with 5FU/FA chemotherapy). The dose will depend on a number of factors, including the treatment schedule, your body size, your age and general health, your blood counts, how well your liver is working, whether you have had radiation to your abdomen/pelvis, and whether you have any side effects such as diarrhoea.</p><p>&nbsp;</p><p>Only your doctor may assess the duration of treatment.</p><p>&nbsp;</p><p><strong>If you use more </strong><strong>Irinotecan Jazeera </strong><strong>than you should</strong></p><p>Seek emergency medical attention. Overdose symptoms may include some of the serious side effects listed in this leaflet.</p><p>&nbsp;</p><p><strong>If you forget to use </strong><strong>Irinotecan Jazeera</strong></p><p>Call your doctor for instructions if you miss an appointment for your Irinotecan Jazeera injection.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Some side effect could be serious. You must immediately contact your doctor if you experience any of those following serious side effects (see section 2).</p><p>Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.</p><ul><li>&nbsp; &nbsp; Diarrhoea (see section 2)</li></ul><p>-&nbsp;&nbsp;&nbsp; Early diarrhoea: Occurring within 24 hours of receiving this medicine, accompanied by symptoms runny nose, increased salivation, watery eyes, sweating, flushing, abdominal cramping. (This can occur while the medicine is being administered. If so, alert your healthcare professional promptly. Medication can be given to stop and/or lessen this early side effect).</p><p>-&nbsp;&nbsp;&nbsp; Late diarrhoea: Occurring greater than 24 hours of receiving this medicine. Because of concerns of dehydration and electrolyte imbalances with diarrhoea it is important to be in contact with health care professionals for monitoring, and for medication and diet modifications advice.</p><p>&nbsp;</p><p>Talk to your doctor or nurse if you experience any of the symptoms below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Symptoms </strong></p></td><td style="vertical-align:top"><p><strong>Frequency* of occurrence in Monotherapy </strong></p></td><td style="vertical-align:top"><p><strong>Frequency&dagger; of occurrence in Combination Therapy </strong></p></td></tr><tr><td style="vertical-align:top"><p>Abnormally low number of white blood cells which could put you at increased risk for infection</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Low number of red blood cells causing tiredness and shortness of breath</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Cholinergic syndrome (see Take special care with Irinotecan Jazeera)<strong> </strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hair loss (reversible)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Inflammation of mucous membranes</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Feeling weak and having no energy</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Low number of platelets (blood cells that help with clotting) which may cause bruising or bleeding</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal liver function test values</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Low number of white blood cells with fever</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Difficulty in passing stools</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal kidney function test values</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Not reported</p></td></tr></tbody></table><p>* Very common: may affect more than 1 in 10 people</p><p>&dagger; Common: may affect up to 1 in 10 people</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data </strong></p><ul><li>&nbsp; &nbsp; Severe, persistent or bloody diarrhoea (which may be associated with stomach pain or fever) caused by bacteria called (Clostridium difficile)</li><li>&nbsp; &nbsp; Blood infection</li><li>&nbsp; &nbsp; Dehydration (due to diarrhoea and vomiting)</li><li>&nbsp; &nbsp; Dizziness, rapid heart beat and pale skin (a condition called hypovolaemia)</li><li>&nbsp; &nbsp; Allergic reaction</li><li>&nbsp; &nbsp; Temporary speech disorders during or shortly after treatment</li><li>&nbsp; &nbsp; Pins and needles</li><li>&nbsp; &nbsp; High blood pressure (during or after infusion)</li><li>&nbsp; &nbsp; Heart problems*</li><li>&nbsp; &nbsp; Lung disease causing wheezing and shortness of breath (see section 2)</li><li>&nbsp; &nbsp; Hiccups</li><li>&nbsp; &nbsp; Intestinal blockage</li><li>&nbsp; &nbsp; Enlarged colon</li><li>&nbsp; &nbsp; Bleeding from the bowels</li><li>&nbsp; &nbsp; Inflammation of the large intestine</li><li>&nbsp; &nbsp; Abnormal lab test results</li><li>&nbsp; &nbsp; Hole in the intestine</li><li>&nbsp; &nbsp; Fatty liver disease</li><li>&nbsp; &nbsp; Skin reactions</li><li>&nbsp; &nbsp; Reactions at the site where the medicine was administered</li><li>&nbsp; &nbsp; Low level of potassium in the blood</li><li>&nbsp; &nbsp; Low level of salt in the blood mostly related with diarrhoea and vomiting</li><li>&nbsp; &nbsp; Muscle cramps</li><li>&nbsp; &nbsp; Kidney problems*</li><li>&nbsp; &nbsp; Low blood pressure*</li><li>&nbsp; &nbsp; Fungal infections</li><li>&nbsp; &nbsp; Viral infections</li></ul><p>&nbsp;</p><p>* Infrequent cases of these events have been observed in patients who experienced episodes of dehydration associated with diarrhoea and/or vomiting, or infections of the blood.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Keep this medicine out of the sight and reach of children.</p><p style="text-align:justify">Store below 25&deg;C.</p><p style="text-align:justify">Protect from light.</p><p style="text-align:justify">Store in the original package.</p><p style="text-align:justify">After dilution: The medicine will be given to you within 24 hours of dilution. The diluted solution may have been stored at 2 to 8&deg;C in a refrigerator.</p><p style="text-align:justify">Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p style="text-align:justify">Do not use this medicine if you notice any visible signs of deterioration.</p><p style="text-align:justify">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is irinotecan hydrochloride trihydrate.</p><p>&nbsp;</p><p>Each 2 ml of Irinotecan Jazeera 40 mg/2 ml Concentrate for Solution for Infusion contains 40 mg irinotecan hydrochloride trihydrate.</p><p>&nbsp;</p><p>Each 5 ml of Irinotecan Jazeera 100 mg/5 ml Concentrate for Solution for Infusion contains 100 mg irinotecan hydrochloride trihydrate.</p><p>&nbsp;</p><p>The other ingredients are sorbitol, lactic acid, hydrochloric acid, sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Irinotecan Jazeera 40 mg/2 ml Concentrate for Solution for Infusion is a clear yellow solution in type I amber glass vials sealed with grey stoppers and aluminum flip-off caps with red cover.

Irinotecan Jazeera 100 mg/5 ml Concentrate for Solution for Infusion is a clear yellow solution in type I amber glass vials sealed with grey stoppers and aluminum flip-off caps with yellow cover.


Pack size: 
Irinotecan Jazeera 40 mg/2 ml Concentrate for Solution for Infusion: 1 Vial (2 ml).

Irinotecan Jazeera 100 mg/5 ml Concentrate for Solution for Infusion: 1 Vial (5 ml).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Manufacturer </strong></p><p>Thymoorgan Pharmazie GmbH<br />Schiffgraben 23,<br />38690 Goslar,<br />Germany<br />Tel: + (49-5324) 77010<br />Fax: + (49- 5324) 770130</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 12/2022; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ايرينوتيكان جزيرة دواء مضاد للسرطان يحتوي على المادة الفعالة هيدروكلوريد الايرينوتيكان ثلاثي الماء.</p><p>&nbsp;</p><p dir="RTL">يتداخل هيدروكلوريد الايرينوتيكان ثلاثي الماء مع نمو وانتشار الخلايا السرطانية في الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم ايرينوتيكان جزيرة مع أدوية أخرى لعلاج المرضى الذين يعانون من سرطان في حالة متقدمة أو السرطان النقيلي في القولون أو المستقيم.</p><p>&nbsp;</p><p dir="RTL">يمكن استخدام ايرينوتيكان جزيرة وحده لدى المرضى الذين يعانون من السرطان النقيلي في القولون أو المستقيم الذين تكرر مرضهم أو تطور المرض بعد علاج أولي معتمد على فلورويوراسيل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم ايرينوتيكان جزيرة</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; إذا كنت تعاني من مرض التهاب الأمعاء المزمن و/أو انسداد الأمعاء</li><li>&nbsp; &nbsp; إذا كنت تعاني من حساسية تجاه هيدروكلوريد الايرينوتيكان ثلاثي الماء أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</li><li>&nbsp; &nbsp; إذا كنتِ مرضعاً (انظري القسم 2)</li><li>&nbsp; &nbsp; إذا كان مستوى البيليروبين لديك أعلى من 3 أضعاف الحد الأعلى للمعدل الطبيعي</li><li>&nbsp; &nbsp; إذا كنت تعاني من قصور حاد في نخاع العظام</li><li>&nbsp; &nbsp; إذا كنت تعاني من سوء حالتك العامة (مؤشر حالة أداء WHO أعلى من 2)</li><li>&nbsp; &nbsp; إذا كنت تتناول أو تناولت مؤخراً نبتة سانت جون (مستخلص عشبي يحتوي على الحشيشة)</li><li>&nbsp; &nbsp; إذا كنت ستأخذ أو أخذت مؤخراً لقاحات حية موهنة (لقاحات ضد الحمى الصفراء، الجديري المائي، الهربس النطاقي، الحصبة، النكاف، الحصبة الألمانية، السل، فيروس الروتا، الإنفلونزا) وخلال 6 أشهر بعد التوقف عن أخذ العلاج الكيميائي</li></ul><p dir="RTL">إذا كنت تأخذ ايرينوتيكان جزيرة بالتزامن مع أدوية أخرى، فيرجى التأكد من قراءة نشرة الدواء الخاصة بالأدوية الأخرى فيما يتعلق بموانع الاستخدام الإضافية.</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض قبل استخدام ايرينوتيكان جزيرة.</p><ul dir="rtl"><li>&nbsp; &nbsp; إذا كنت تعاني من متلازمة&nbsp;جيلبرت، حالة موروثة والتي قد تسبب ارتفاع في مستوى البيلروبين واليرقان (اصفرار في الجلد والعينين).</li></ul><p>&nbsp;</p><p dir="RTL">يجب توخي الحذر الشديد عند استخدام ايرينوتيكان جزيرة. يجب أن يقتصر استخدام ايرينوتيكان جزيرة على الوحدات المتخصصة في إعطاء العلاج الكيميائي السام للخلايا ولا يتم أخذه إلا تحت إشراف طبيب مؤهل في استخدام العلاج الكيميائي المضاد للسرطان.</p><p>&nbsp;</p><p dir="RTL"><em>الإسهال </em></p><p dir="RTL">يمكن أن يسبب ايرينوتيكان إسهالاً قد يكون حاداً في بعض الحالات. قد يبدأ هذا بعد بضع ساعات أو يومين من تسريب الدواء. في حال عدم أخذ علاج لذلك، قد يؤدي إلى حدوث جفاف واختلالات كيميائية خطيرة، يمكن أن تكون مهددة للحياة. سيصف لك طبيبك دواءً للمساعدة في منع هذا الأثر الجانبي أو السيطرة عليه. تأكد من حصولك على الدواء في الحال، بحيث يكون لديك في المنزل عند حاجتك إليه.</p><ul dir="rtl"><li>&nbsp; &nbsp; خذ الدواء بالطريقة الموصوفة عند ظهور أولى علامات الإسهال أو حركات متكررة في الأمعاء.</li><li>&nbsp; &nbsp; اشرب كميات كبيرة من الماء و(أو) مشروبات مالحة (مياه غازية، صودا أو حساء).</li><li>&nbsp; &nbsp; اتصل بطبيبك أو الممرض لإعلامهما إذا كنت لا تزال تعاني من إسهال، لا سيما إذا استمر لأكثر من 24 ساعة، أو إذا شعرت بدوخة، دوار أو إغماء.</li></ul><p>&nbsp;</p><p dir="RTL"><em>قلة العدلات (انخفاض في بعض خلايا الدم البيضاء) </em></p><p dir="RTL">يمكن لهذا الدواء أن يخفض عدد خلايا الدم البيضاء في جسمك، لا سيما في الأسابيع التي تلي إعطاء الدواء. يمكن أن يزيد هذا من خطر الإصابة بعدوى. تأكد من إخبار طبيبك أو الممرض على الفور إذا ظهرت عليك أي علامات للعدوى، مثل حمى (38&deg; مئوية أو أعلى)، قشعريرة، ألم عند التبول، سعال جديد، أو خروج بلغم. تجنب الاقتراب من المرضى أو المصابين بعدوى. أخبر طبيبك على الفور إذا ظهرت عليك علامات عدوى.</p><p>&nbsp;</p><p dir="RTL"><em>مراقبة الدم </em></p><p dir="RTL">من المحتمل أن يفحص طبيبك دمك قبل علاجك وفي أثنائه، للتحقق من آثار الدواء على عدد الصفائح الدموية أو على كيمياء الدم. وبناءً على نتائج الاختبار، قد تحتاج إلى أدوية للمساعدة في علاج الآثار. قد يحتاج طبيبك أيضاً إلى تقليل الجرعة التالية من هذا الدواء أو تأخيرها، أو حتى إيقاف أخذ الدواء كله. واظب على جميع مواعيدك للذهاب للطبيب والفحوصات المخبرية.</p><p>&nbsp;</p><p dir="RTL">قد يقلل هذا الدواء من عدد الصفائح الدموية في الأسابيع التي تلي إعطاءه، مما قد يزيد من خطر النزف لديك. تحدث مع طبيبك قبل تناول أي أدوية أو مكملات قد تؤثر على قدرة جسمك على وقف النزف، مثل الأسبرين أو الأدوية المحتوية على الأسبرين، الوارفارين أو فيتامين ﻫ، أخبر طبيبك على الفور إذا ظهر عليك تكدم غير عادي أو نزف مثل نزف من الأنف، أو نزف اللثة عند تنظيف أسنانك، أو براز أسود، قطراني.</p><p>&nbsp;</p><p dir="RTL"><em>غثيان وقيء </em></p><p dir="RTL">قد تشعر بالغثيان والقيء في اليوم الذي تأخذ فيه هذا الدواء أو في الأيام القليلة الأولى التالية. قد يعطيك طبيبك دواءً قبل العلاج للمساعدة في منع الغثيان والقيء. من المحتمل أن يصف لك طبيبك أدوية مضادة للغثيان يمكنك تناولها في المنزل. احتفظ بهذه الأدوية في المتناول لتجدها عند الحاجة إليها. اتصل بطبيبك إذا كنت لا تستطيع تناول السوائل عن طريق الفم بسبب الغثيان والقيء.</p><p>&nbsp;</p><p dir="RTL"><em>المتلازمة الكولينية الحادة </em></p><p dir="RTL">قد يؤثر هذا الدواء على جزء من جهازك العصبي الذي يتحكم في إفرازات الجسم، وهذا يؤدي إلى ما يعرف بالمتلازمة الكولينية. يمكن أن تشمل الأعراض سيلان الأنف، زيادة اللعاب، الدموع الزائدة في العين، التعرق، احمرار الوجه، تشنجات البطن والإسهال. أخبر طبيبك أو الممرض على الفور إذا لاحظت أياً من هذه الأعراض، حيث توجد أدوية يمكن أن تساعد في السيطرة عليها.</p><p>&nbsp;</p><p dir="RTL"><em>اضطرابات الرئة </em></p><p dir="RTL">نادراً ما يعاني الأشخاص الذين يأخذون هذا الدواء من مشاكل رئوية خطيرة، أخبر طبيبك على الفور إذا عانيت من سعال جديد أو تفاقم السعال الحالي، صعوبة في التنفس وحمى. قد يحتاج طبيبك إلى إيقاف علاجك لمعالجة هذه المشكلة.</p><p>&nbsp;</p><p dir="RTL">قد يزيد هذا الدواء من خطر الإصابة بجلطات دموية كبيرة في أوردة الساقين أو الرئتين، التي يمكن أن تنتقل إلى أجزاء أخرى من الجسم مثل الرئتين أو الدماغ. أخبر طبيبك على الفور إذا لاحظت ألماً في الصدر، ضيقاً في التنفس، أو تورماً، ألماً، احمراراً أو شعوراً بالسخونة في الذراع أو الساق.</p><p>&nbsp;</p><p dir="RTL"><em>التهاب معوي مزمن و/أو انسداد معوي </em></p><p dir="RTL">اتصل بطبيبك إذا كان تعاني من ألم في بطنك ولا يمكنك التغوط، لا سيما إذا كنت تعاني كذلك من الانتفاخ وفقدان الشهية.</p><p>&nbsp;</p><p dir="RTL"><em>العلاج الإشعاعي </em></p><p dir="RTL">إذا تلقيت مؤخراً علاجاً إشعاعياً للحوض أو البطن، فقد تزداد خطورة الإصابة بكبت نقي العظم. يُرجى التحدث مع طبيبك قبل البدء في أخذ ايرينوتيكان جزيرة.</p><p>&nbsp;</p><p dir="RTL"><em>وظيفة الكُلى </em></p><p dir="RTL">تم الإبلاغ عن حدوث اختلال وظيفي في الكلى.</p><p>&nbsp;</p><p dir="RTL"><em>الاضطرابات القلبية </em></p><p dir="RTL">أخبر طبيبك إذا كنت تعاني/عانيت من مرض في القلب أو إذا كنت قد تلقيت أدوية مضادة للسرطان من قبل. سيراقبك طبيبك عن كثب ويناقش معك كيف يمكن تقليل عوامل الخطر (على سبيل المثال التدخين، ارتفاع ضغط الدم والمحتويات العالية من الدهون).</p><p>&nbsp;</p><p dir="RTL"><em>اضطرابات الأوعية الدموية </em></p><p dir="RTL">نادراً ما يرتبط ايرينوتيكان باضطرابات تدفق الدم (تجلطات الدم في أوعية الساقين والرئتين) ونادراً ما يحدث ذلك مع المرضى الذين يعانون من عوامل خطر متعددة.</p><p>&nbsp;</p><p dir="RTL"><em>أعراض أخرى </em></p><p dir="RTL">قد يسبب هذا الدواء تقرحات في الفم أو على الشفاه، ويكون ذلك غالباً خلال الأسابيع القليلة الأولى بعد بدء العلاج. قد يسبب ذلك ألماً في الفم، نزفاً، أو حتى صعوبة في تناول الطعام. يمكن لطبيبك أو الممرض اقتراح طرق للتخفيف من وطأة ذلك، مثل تغيير طريقة تناولك للطعام أو طريقة تنظيف أسنانك. يمكن لطبيبك، في حالة الضرورة، أن يصف لك دواءً للمساعدة في تخفيف الألم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المعلومات عن منع الحمل والرضاعة، ارجع إلى المعلومات المقدمة أدناه تحت قسم منع الحمل، الحمل، الرضاعة الطبيعية والخصوبة.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو طبيب الأسنان أنك تأخذ هذا الدواء إذا كنت تنوي إجراء عملية جراحية أو الخضوع لأي إجراء طبي.</p><p>&nbsp;</p><p dir="RTL">في حال أخذ هذا الدواء مع أدوية أخرى مضادة للسرطان لحالتك، يُرجى التأكد من قراءة النشرات الدوائية للأدوية الأخرى.</p><p>&nbsp;</p><p dir="RTL">إذا أخبرك طبيبك أنك تعاني من حساسية مفرطة لبعض أنواع السكر، فاتصل بطبيبك قبل أخذ هذا المنتج الدوائي.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وايرينوتيكان جزيرة</strong></p><p dir="RTL">يمكن أن يتفاعل ايرينوتيكان جزيرة مع عدد من الأدوية والمكملات، التي قد ترفع أو تخفض مستوى الدواء في دمك. أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً أو قد تأخذ أياً مما يلي:</p><ul dir="rtl"><li>&nbsp; &nbsp; الأدوية المستخدمة لعلاج النوبات التشنجية (كاربامازيبين، فينوباربيتال، فينيتوين وفوسفينيتوين)</li><li>&nbsp; &nbsp; الأدوية المستخدمة لعلاج العدوى الفطرية (كيتوكونازول، إيتراكونازول، فوريكونازول وبوساكونازول)</li><li>&nbsp; &nbsp; الأدوية المستخدمة لعلاج العدوى البكتيرية (كلاريثروميسين، إيريثروميسين وتيليثروميسين)</li><li>&nbsp; &nbsp; الأدوية المستخدمة لعلاج السل (ريفامبيسين وريفابوتين)</li><li>&nbsp; &nbsp; نبتة سانت جون (مكمل غذائي عشبي)</li><li>&nbsp; &nbsp; لقاحات حية موهنة</li><li>&nbsp; &nbsp; الأدوية المستخدمة لعلاج فيروس نقص المناعة البشري (إندينافير، ريتونافير، أمبرينافير، فوسامبرينافير، نلفينافير، أتازانافير، وغيرها)</li><li>&nbsp; &nbsp; الأدوية المستخدمة لقمع جهاز المناعة في الجسم لمنع رفض العضو المزروع (سيكلوسبورين وتاكروليمس)</li><li>&nbsp; &nbsp; الأدوية المستخدمة لعلاج السرطان (ريجورافينيب، كريزوتينيب، إديلاليسيب وأبالوتاميد)</li><li>&nbsp; &nbsp; مضادات فيتامين ك (مميعات الدم الشائعة مثل وارفارين)</li><li>&nbsp; &nbsp; الأدوية المستخدمة لإرخاء العضلات المستخدمة أثناء التخدير العام والجراحة (سوكساميثونيوم)</li><li>&nbsp; &nbsp; 5-فلورويوراسيل/حمض الفولينيك</li><li>&nbsp; &nbsp; بيفاسيزوماب (مثبط لنمو الأوعية الدموية)</li><li>&nbsp; &nbsp; سيتوكسيماب (مثبط مستقبلات عامل نمو البشرة)</li></ul><p>&nbsp;</p><p dir="RTL">أخبر طبيبك، الصيدلي أو الممرض قبل إعطائك ايرينوتيكان جزيرة إذا كنت تأخذ مسبقاً، أو أخذت حديثاً معالجة كيميائية (ومعالجة إشعاعية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تبدأ أو تتوقف عن أخذ أي أدوية أثناء أخذك لايرينوتيكان جزيرة دون استشارة طبيبك أولاً.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يسبب هذا الدواء إسهالاً حاداً. حاول تجنب الملينات وملينات البراز أثناء أخذ هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد توجد أدوية أخرى تتفاعل مع ايرينوتيكان جزيرة. استشر طبيبك، الصيدلي أو الممرض بشأن الأدوية الأخرى، الأعشاب والمكملات، وما إذا كان الكحول يمكن أن يؤدي إلى حدوث مشاكل خلال أخذ هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>منع الحمل، </strong><strong>الحمل، الرضاعة والخصوبة</strong><br /><em>منع الحمل </em><br />إذا كنت امرأة في عمر الإنجاب، فيجب عليك استخدام وسائل منع الحمل الفعّالة خلال فترة أخذ الدواء ولمدة تصل إلى 6 أشهر بعد وقف تلقي العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كرجل، عليك استخدام وسائل منع الحمل الفعّالة خلال فترة أخذ الدواء ولمدة تصل إلى 3 أشهر بعد وقف تلقي العلاج. من المهم التحقق من طبيبك عن أنواع تنظيم الحمل التي يمكن استخدامها مع هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الحمل </em><br />قد يسبب هذا الدواء مشاكل للجنين إذا تم أخذه في وقت تكون الجنين أو أثناء الحمل. قبل بدء العلاج، يجب أن يتأكد طبيبك من أنك لست حاملاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت حاملاً ، تعتقدين بأنك حامل أو تخططين لذلك، استشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><em>الرضاعة </em><br />إن كمية ايرينوتيكان وناتج استقلابه قد تم قياسها في حليب الثدي. يجب وقف الرضاعة خلال فترة علاجك بهذا الدواء.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ مرضعاً، استشيري طبيبك أو الصيدلي طلباً للنصيحة قبل أخذ هذه الدواء.</p><p>&nbsp;</p><p dir="RTL"><em>الخصوبة </em><br />لم يتم إجراء أي دراسات، ومع ذلك، قد يؤثر هذا الدواء على الخصوبة. تحدث مع طبيبك قبل أخذ هذا الدواء حول الخطر المحتمل والخيارات التي من المحتمل ان تحافظ على قدرتك على الحصول على الأطفال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />قد تلاحظ أنك تشعر بالدوار و/أو لديك مشكلة في الرؤية في أول 24 ساعة أو نحو ذلك بعد أخذك هذا الدواء. لا تقم بقيادة السيارة أو تشغيل الآلات إذا كنت تعاني من هذا التأثير الجانبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ايرينوتيكان جزيرة</strong><strong> على السوربيتول</strong><strong> والصوديوم</strong><br />يحتوي ايرينوتيكان جزيرة على السوربيتول. تحتوي كل زجاجة من ايرينوتيكان جزيرة 40 ملغم/2 مللتر و100 ملغم/5 مللتر مركز للتخفيف للتسريب على 90 ملغم أو 225 ملغم سوربيتول؛ على التوالي. يعتبر السوربيتول مصدر للفركتوز. إذا كنت (أو طفلك) تعاني من عدم التحمل الوراثي للفركتوز، وهو اضطراب وراثي نادر، فيجب ألا تأخذ أنت (أو طفلك) هذا الدواء. لا يستطيع المرضى الذين يعانون من عدم التحمل الوراثي للفركتوز تكسير الفركتوز، ما قد يسبب آثاراً جانبية خطيرة.</p><p>&nbsp;</p><p dir="RTL">يجب أن تخبر طبيبك قبل أخذ هذا الدواء إذا كنت أنت (أو طفلك) مصاباً بعدم التحمل الوراثي للفركتوز أو إذا لم يعد بإمكان طفلك تناول الأطعمة أو المشروبات الحلوة لأنه يشعر بالغثيان أو القيء أو يعاني من آثار مزعجة مثل الانتفاخ، تقلصات المعدة أو الإسهال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي ايرينوتيكان جزيرة على الصوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل زجاجة، وهذا يعني أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً باستخدام دوائك كما وصفه لك طبيبك تماماً. تحقق مع طبيبك إذا كنت غير متأكد.</p><p>&nbsp;</p><p dir="RTL">يتولى متخصصو الرعاية الصحية مسؤولية إعطائك ايرينوتيكان جزيرة.</p><p>&nbsp;</p><p dir="RTL">قد يوصي طبيبك بإجراء اختبار حمض نووي قبل جرعتك الأولى من ايرينوتيكان جزيرة.</p><p>&nbsp;</p><p dir="RTL">بعض الناس أكثر عرضة وراثياً للإصابة ببعض الآثار الجانبية للدواء.</p><p>&nbsp;</p><p dir="RTL">تعتمد كمية ايرينوتيكان جزيرة التي ستأخذها على الكثير من العوامل، منها طولك ووزنك، صحتك العامة أو مشاكلك الصحية الأخرى، ونوع السرطان أو الحالة التي يتم علاجها. سيحدد طبيبك الجرعة والجدول الزمني لك.</p><p>&nbsp;</p><p dir="RTL">يتم حقن ايرينوتيكان جزيرة في الوريد عن طريق الحقن الوريدي. ستتلقى هذا الحقن في عيادة أو مستشفى. يجب إعطاء ايرينوتيكان جزيرة ببطء، ويمكن أن يستغرق اكتمال التسريب الوريدي ما يصل إلى 90 دقيقة.</p><p>&nbsp;</p><p dir="RTL">قد يتم إعطاؤك أدوية أخرى لمنع الغثيان، القيء، الإسهال والآثار الجانبية الأخرى أثناء تلقيك ايرينوتيكان جزيرة. قد تحتاج إلى الاستمرار في استخدام هذه الأدوية لمدة يوم على الأقل بعد حقنك بايرينوتيكان جزيرة.</p><p>&nbsp;</p><p dir="RTL">أخبرٍ مقدمي الرعاية إذا شعرت بأي حرقان، ألم، أو تورم حول موضع الإبرة الوريدية عند حقن ايرينوتيكان جزيرة. إذا تسرب الدواء من الوريد فقد يتسبب في تلف الأنسجة. أبلغ اختصاصي الرعاية الصحية الخاص بك على الفور إذا شعرت بألم أو لاحظت احمراراً أو تورماً في موضع الحقن الوريدي أثناء تلقيك ايرينوتيكان جزيرة.</p><p>&nbsp;</p><p dir="RTL">يوجد حالياً العديد من جداول العلاج الموصى بها لايرينوتيكان جزيرة. عادةً ما يُعطى مرة واحدة كل 3 أسابيع (يُعطى ايرينوتيكان جزيرة بمفرده) أو مرة كل أسبوعين (يُعطى ايرينوتيكان جزيرة مع العلاج الكيماوي 5FY/FA). ستعتمد الجرعة على عدد من العوامل، يشمل ذلك جدول العلاج، حجم جسمك، عمرك وصحتك العامة، عدد كريات الدم لديك، ومدى جودة عمل كبدك، وإذا ما كنت قد تعرضت للإشعاع على البطن/الحوض، وإذا ما كنت تعاني من أية آثار جانبية مثل الإسهال.</p><p>&nbsp;</p><p dir="RTL">يمكن لطبيبك فقط تقييم مدة العلاج.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا استخدمت </strong><strong>ايرينوتيكان جزيرة أكثر من اللازم</strong><br />اطلب العناية الطبية الطارئة. قد تشمل أعراض الجرعة الزائدة بعض الآثار الجانبية الخطيرة المذكورة في هذه النشرة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام </strong><strong>ايرينوتيكان جزيرة</strong><br />اتصل بطبيبك للحصول على تعليمات إذا فوت موعد حقن ايرينوتيكان جزيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">قد تكون بعض الآثار الجانبية خطيرة. يجب عليك الاتصال بطبيبك على الفور إذا واجهت أياً من الآثار الجانبية الخطيرة التالية (انظر القسم 2).</p><p dir="RTL">اطلب المساعدة الطبية الطارئة إذا ظهر عليك أي علامات رد الفعل التحسسي التالية: الشرى، صعوبة في التنفس، تورم الوجه، الشفتين، اللسان أو الحلق.</p><ul dir="rtl"><li>&nbsp; &nbsp; الإسهال (انظر القسم 2)</li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الإسهال المبكر: يحدث خلال 24 ساعة من تلقي هذا الدواء، مصحوباً بأعراض مثل سيلان الأنف، زيادة إفراز اللعاب، تدمع العينين، تعرق، احمرار، تقلصات في البطن. (يمكن أن يحدث هذا أثناء إعطاء الدواء. في حالة حدوث ذلك، أبلغ اختصاصي الرعاية الصحية الخاص بك على الفور. يمكن إعطاء دواء لوقف و/أو تقليل هذا التأثير الجانبي المبكر).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الإسهال المتأخر: يحدث بعد مرور أكثر من 24 ساعة من تلقي هذا الدواء. نظراً لمخاوف الإصابة بالجفاف واختلالات الكهارل مع الإسهال، من المهم أن تكون على تواصل مع متخصصي الرعاية الصحية للمتابعة، والحصول على نصيحة حول الأدوية وتعديلات النظام الغذائي.</p><p>&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الممرض إذا عانيت من أي من الأعراض الواردة أدناه:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأعراض </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>تكرار* الحدوث في العلاج الأحادي </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>تكرار<sup>&dagger;</sup> الحدوث في العلاج بأكثر من دواء </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض عدد خلايا الدم البيضاء بشكل غير طبيعي، مما قد يعرضك لخطر تزايد الإصابة بالعدوى</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض عدد خلايا الدم الحمراء، سوف يسبب التعب وضيق التنفس</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نقص الشهية</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">متلازمة الكولين (انظر قسم يجب توخي الحذر الشديد عند استخدام ايرينوتيكان جزيرة)<strong> </strong></p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قيء</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">غثيان</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ألم في البطن</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تساقط الشعر (يمكن علاجه)</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الأغشية المخاطية</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حمّى</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">شعور بالضعف والخمول</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نقص عدد الصفائح الدموية (خلايا الدم التي تساعد على التجلط) مما قد يسبب كدمات أو نزف</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قيم غير طبيعية في اختبار وظائف الكبد</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td><td style="vertical-align:top"><p dir="RTL">شائعة جداً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عدوى</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نقص في عدد خلايا الدم البيضاء مصحوباً بحمّى</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">صعوبة في التبرز</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قيم غير طبيعية في اختبار وظائف الكلى</p></td><td style="vertical-align:top"><p dir="RTL">شائعة</p></td><td style="vertical-align:top"><p dir="RTL">لم يُبلغ عنها</p></td></tr></tbody></table><p dir="RTL">*آثار جانبية شائعة جداً: قد تؤثر على أكثر من شخص واحد من بين 10 أشخاص</p><p dir="RTL">&dagger; آثار جانبية شائعة: قد تؤثر على ما يصل إلى شخص واحد من بين 10 أشخاص</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير معروفة: لا يمكن تقدير معدل تكرارها من البيانات المتوفرة </strong></p><ul dir="rtl"><li>&nbsp; &nbsp; الإسهال الحاد، المستمر أو الدموي (الذي قد يصاحبه ألم في المعدة أو حمّى) تسببه بكتيريا تسمى (المطثية العسيرة)</li><li>&nbsp; &nbsp; عدوى الدم</li><li>&nbsp; &nbsp; جفاف (بسبب الإسهال والقيء)</li><li>&nbsp; &nbsp; دوخة، سرعة نبضات القلب وشحوب الجلد (حالة تسمى نقص حجم الدم)</li><li>&nbsp; &nbsp; رد فعل تحسسي</li><li>&nbsp; &nbsp; اضطرابات الكلام المؤقتة خلال العلاج أو بعده بفترة وجيزة</li><li>&nbsp; &nbsp; الإحساس بالوخز كالإبر والدبابيسس</li><li>&nbsp; &nbsp; ارتفاع ضغط الدم (أثناء التسريب وبعده)</li><li>&nbsp; &nbsp; مشاكل في القلب*</li><li>&nbsp; &nbsp; مرض الرئة يسبب أزيزاً وضيقاً في التنفس (انظر القسم 2)</li><li>&nbsp; &nbsp; فواق</li><li>&nbsp; &nbsp; انسداد معوي</li><li>&nbsp; &nbsp; تضخم القولون</li><li>&nbsp; &nbsp; نزف من الأمعاء</li><li>&nbsp; &nbsp; التهاب الأمعاء الغليظة</li><li>&nbsp; &nbsp; نتائج فحوصات مخبرية غير طبيعية</li><li>&nbsp; &nbsp; ثقب في الأمعاء</li><li>&nbsp; &nbsp; مرض الكبد الدهني</li><li>&nbsp; &nbsp; التفاعلات الجلدية</li><li>&nbsp; &nbsp; ردود فعل في موضع إعطاء الدواء</li><li>&nbsp; &nbsp; انخفاض مستوى البوتاسيوم في الدم</li><li>&nbsp; &nbsp; غالباً ما يرتبط انخفاض مستوى الصوديوم في الدم بالإسهال والقيء</li><li>&nbsp; &nbsp; تشنج العضلات</li><li>&nbsp; &nbsp; مشاكل في الكلى*</li><li>&nbsp; &nbsp; انخفاض ضغط الدم*</li><li>&nbsp; &nbsp; حالات عدوى فطرية</li><li>&nbsp; &nbsp; حالات عدوى فيروسية</li></ul><p>&nbsp;</p><p dir="RTL">* لقد تمت ملاحظة حالات نادرة من هذه الآثار لدى المرضى الذين عانوا من نوبات جفاف مصحوبة بإسهال و/أو قيء أو أحدهما، أو حالات عدوى في الدم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p style="text-align:justify">يحفظ عند درجة حرارة أقل من 25&deg; مئوية.</p><p style="text-align:justify">احمه من الضوء.</p><p style="text-align:justify">يحفظ داخل العبوة الأصلية.</p><p style="text-align:justify">بعد التخفيف: سيتم إعطاؤك الدواء خلال 24 ساعة من التخفيف. يمكن أن يكون قد تم حفظ المحلول المخفف عند درجة حرارة تتراوح ما بين 2 إلى 8˚ مئوية في الثلاجة.</p><p style="text-align:justify">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p style="text-align:justify">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p style="text-align:justify">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي هيدروكلوريد الايرينوتيكان ثلاثي الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل 2 مللتر من ايرينوتيكان جزيرة 40 ملغم/2 مللتر مركز للتخفيف للتسريب على 40 ملغم هيدروكلوريد الايرينوتيكان ثلاثي الماء.</p><p>&nbsp;</p><p dir="RTL">يحتوي كل 5 مللتر من ايرينوتيكان جزيرة 100 ملغم/5 مللتر مركز للتخفيف للتسريب على 100 ملغم هيدروكلوريد الايرينوتيكان ثلاثي الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي سوربيتول، حمض اللاكتيك، حمض الهيدروكلوريك، هيدروكسيد الصوديوم وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ايرينوتيكان جزيرة 40 ملغم/2 مللتر مركز للتخفيف للتسريب هو محلول صافٍ أصفر في زجاجات كهرمانية من النوع رقم واحد مغطاة بسدادات رمادية وأغطية من الألومنيوم قابلة للفتح لأعلى مع غطاء أحمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ايرينوتيكان جزيرة 100 ملغم/5 مللتر مركز للتخفيف للتسريب هو محلول صافٍ أصفر في زجاجات كهرمانية من النوع رقم واحد مغطاة بسدادات رمادية وأغطية من الألومنيوم قابلة للفتح لأعلى مع غطاء أصفر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة:</p><p dir="RTL">ايرينوتيكان جزيرة 40 ملغم/2 مللتر مركز للتخفيف للتسريب: زجاجة واحدة (2 مللتر).</p><p dir="RTL">&nbsp;</p><p>ايرينوتيكان جزيرة 100 ملغم/5 مللتر مركز للتخفيف للتسريب: زجاجة واحدة (5 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق</strong><strong> </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة أدوية ثايمورغان ذات المسؤولية المحدودة</p><p dir="RTL">شارع شيفجرابين 23،</p><p dir="RTL">38690 غوسلار،</p><p dir="RTL">ألمانيا</p><p dir="RTL">هاتف: 77010 (5324-49) +</p><p dir="RTL">فاكس: 770130 (5324-49) +</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 12/2022، رقم النسخة SA3.0
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Irinotecan Jazeera 40 mg/2 ml Concentrate for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 2 ml of Irinotecan Jazeera 40 mg/2 ml Concentrate for Solution for Infusion contains 40 mg irinotecan hydrochloride trihydrate. 

Excipients with known effect: Sorbitol and sodium.  

‘For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for Solution for Infusion.

Clear yellow solution. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irinotecan Jazeera is indicated for the treatment of patients with advanced colorectal cancer:</p><ul><li>&nbsp;In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,</li><li>&nbsp;As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.</li></ul><p>Irinotecan Jazeera in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy (see section 5.1).</p><p>&nbsp;</p><p>Irinotecan Jazeera in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.</p><p>&nbsp;</p><p>Irinotecan Jazeera in combination with capecitabine with or without bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Posology </em></strong></p><p>For adults only. Irinotecan Jazeera solution for infusion should be infused into a peripheral or central vein.</p><p><em>&nbsp;</em></p><p><strong>Recommended dosage:</strong></p><p><u>In monotherapy (for previously treated patient)</u></p><p>The recommended dosage of Irinotecan Jazeera is 350 mg/m&sup2; administered as an intravenous infusion over a 30- to 90- minute period every three weeks (see sections 4.4 and 6.6).</p><p>&nbsp;</p><p><u>In combination therapy (for previously untreated patient)</u></p><p>Safety and efficacy of Irinotecan Jazeera in combination with 5-fluorouracil (5FU) and folinic acid (FA) have been assessed with the following schedule (see section 5.1).</p><ul><li>&nbsp;Irinotecan Jazeera plus 5FU/FA in every 2 weeks schedule</li></ul><p>The recommended dose of Irinotecan Jazeera is 180 mg/m&sup2; administered once every 2 weeks as an intravenous infusion over a 30- to 90-minute period, followed by infusion with folinic acid and 5 fluorouracil.</p><p>&nbsp;</p><p>For the posology and method of administration of concomitant cetuximab, refer to the product information for this medicinal product.</p><p>&nbsp;</p><p>Normally, the same dose of irinotecan is used as administered in the last cycles of the prior irinotecan-containing regimen. Irinotecan must not be administered earlier than 1 hour after the end of the cetuximab infusion.</p><p>&nbsp;</p><p>For the posology and method of administration of bevacizumab, refer to the bevacizumab summary of product characteristics.</p><p>&nbsp;</p><p>For the posology and method of administration of capecitabine combination, please see section 5.1 and refer to the appropriate sections in the capecitabine summary of product characteristics.</p><p>&nbsp;</p><p><strong>Dosage adjustments:</strong></p><p>Irinotecan Jazeera should be administered after appropriate recovery of all adverse events to Grade 0 or 1 NCI-CTC grading (National Cancer Institute Common Toxicity Criteria) and when treatment-related diarrhoea is fully resolved.</p><p>&nbsp;</p><p>At the start of a subsequent infusion of therapy, the dose of Irinotecan Jazeera, and 5FU when applicable, should be decreased according to the worst grade of adverse events observed in the prior infusion. Treatment should be delayed by 1 to 2 weeks to allow recovery from treatment-related adverse events.</p><p>&nbsp;</p><p>With the following adverse events a dose reduction of 15 to 20% should be applied for Irinotecan Jazeera and/or 5FU when applicable:</p><ul><li>&nbsp;haematological toxicity [neutropenia Grade 4, febrile neutropenia (neutropenia Grade 3-4 and fever Grade 2-4), thrombocytopenia and leukopenia (Grade 4)].</li><li>&nbsp;non-haematological toxicity (Grade 3-4).</li></ul><p>&nbsp;</p><p>Recommendations for dose modifications of cetuximab when administered in combination with irinotecan must be followed according to the product information for this medicinal product.</p><p>In combination with capecitabine for patients 65 years of age or more, a reduction of the starting dose of capecitabine to 800 mg/m<sup>2</sup>&nbsp;twice daily is recommended according to the summary of product characteristics for capecitabine. Refer also to the recommendations for dose modifications in combination regimen given in the summary of product characteristics for capecitabine.</p><p>&nbsp;</p><p><u>Treatment duration:</u></p><p>Treatment with Irinotecan Jazeera should be continued until there is an objective progression of the disease or an unacceptable toxicity.</p><p>&nbsp;</p><p><u>Special populations:</u></p><p><em>Patients with impaired hepatic function:</em></p><p>In monotherapy: Blood bilirubin levels [up to 3 times the upper limit of the normal range (ULN)] in patients with performance status &le; 2, should determine the starting dose of Irinotecan Jazeera. In these patients with hyperbilirubinemia and prothrombin time greater than 50%, the clearance of irinotecan is decreased (see section 5.2) and therefore the risk of hepatotoxicity is increased. Thus, weekly&nbsp;monitoring of complete blood counts should be conducted in this patient population.</p><ul><li>&nbsp; &nbsp; In patients with bilirubin up to 1.5 times the ULN, the recommended dosage of Irinotecan Jazeera is 350 mg/m&sup2;.</li><li>&nbsp; &nbsp; In patients with bilirubin ranging from 1.5 to 3 times the ULN, the recommended dosage of Irinotecan Jazeera is 200 mg/m&sup2;.</li><li>&nbsp; &nbsp; Patients with bilirubin beyond to 3 times the ULN should not be treated with Irinotecan Jazeera (see sections 4.3 and 4.4).</li></ul><p>No data are available in patients with hepatic impairment treated by irinotecan in combination.</p><p>&nbsp;</p><p><em>Patients with impaired renal function</em></p><p>Irinotecan is not recommended for use in patients with impaired renal function, as studies in this population have not been conducted (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Elderly:</em></p><p>No specific pharmacokinetic studies have been performed in elderly. However, the dose should be chosen carefully in this population due to their greater frequency of decreased biological functions. This population should require more intense surveillance (see section 4.4).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Irinotecan in children have not yet been established. No data are available.</p><p>&nbsp;</p><p><strong><em>Method of administration</em></strong></p><p><u>Precautions to be taken before handling or administering the medicinal product</u></p><p>For instructions on dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Chronic inflammatory bowel disease and/or bowel obstruction (see section 4.4).
•	Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
•	Breast-feeding (see sections 4.4 and 4.6).
•	Bilirubin > 3 times the upper limit of the normal range (see section 4.4).
•	Severe bone marrow failure.
•	WHO performance status > 2.
•	Concomitant use with St John's Wort (see section 4.5).
•	Live attenuated vaccines (see section 4.5).

For additional contraindications of cetuximab or bevacizumab or capecitabine, refer to the product information for these medicinal products.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of Irinotecan Jazeera should be confined to units specialised in the administration of cytotoxic chemotherapy and it should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.</p><p>&nbsp;</p><p>Given the nature and incidence of adverse events, Irinotecan will only be prescribed in the following cases after the expected benefits have been weighted against the possible therapeutic risks:</p><ul><li>&nbsp; &nbsp; In patients presenting a risk factor, particularly those with a WHO performance status = 2.</li><li>&nbsp; &nbsp; In the few rare instances where patients are deemed unlikely to observe recommendations regarding management of adverse events (need for immediate and prolonged antidiarrhoeal treatment combined with high fluid intake at onset of delayed diarrhoea). Strict hospital supervision is recommended for such patients. &nbsp;</li></ul><p>&nbsp;</p><p>When Irinotecan Jazeera is used in monotherapy, it is usually prescribed with the every-3-week-dosage schedule. However, the weekly-dosage schedule (see section 5) may be considered in patients who may need a closer follow-up or who are at particular risk of severe neutropenia.</p><p>&nbsp;</p><p><strong>Delayed diarrhoea:</strong></p><p>Patients should be made aware of the risk of delayed diarrhoea occurring more than 24 hours after the administration of Irinotecan Jazeera and at any time before the next cycle. In monotherapy, the median time of onset of the first liquid stool was on day 5 after the infusion of Irinotecan. Patients should quickly inform their physician of its occurrence and start appropriate therapy immediately.</p><p>&nbsp;</p><p>Patients with an increased risk of diarrhoea are those who had a previous abdominal/pelvic radiotherapy, those with baseline hyperleucocytosis, those with performance status &ge; 2 and women. If not properly treated, diarrhoea can be life-threatening, especially if the patient is concomitantly neutropenic.</p><p>&nbsp;</p><p>As soon as the first liquid stool occurs, the patient should start drinking large volumes of beverages containing electrolytes and an appropriate antidiarrhoeal therapy must be initiated immediately. This antidiarrhoeal treatment will be prescribed by the department where Irinotecan has been administered. After discharge from the hospital, the patients should obtain the prescribed medicinal products so that they can treat the diarrhoea as soon as it occurs. In addition, they must inform their physician or the department administering Irinotecan Jazeera when/if diarrhoea is occurring.</p><p>&nbsp;</p><p>The currently recommended antidiarrhoeal treatment consists of high doses of loperamide (4 mg for the first intake and then 2 mg every 2 hours). This therapy should continue for 12 hours after the last liquid stool and should not be modified. In no instance should loperamide be administered for more than 48 consecutive hours at these doses, because of the risk of paralytic ileus, nor for less than 12 hours.</p><p>&nbsp;</p><p>In addition to the antidiarrhoeal treatment, a prophylactic broad-spectrum antibiotic should be given, when diarrhoea is associated with severe neutropenia (neutrophil count &lt;500 cells/mm<sup>3</sup>).</p><p>&nbsp;</p><p>In addition to the antibiotic treatment, hospitalisation is recommended for management of the diarrhoea, in the following cases:</p><ul><li>&nbsp; &nbsp; Diarrhoea associated with fever,</li><li>&nbsp; &nbsp; Severe diarrhoea (requiring intravenous hydration),</li><li>&nbsp; &nbsp; Diarrhoea persisting beyond 48 hours following the initiation of high-dose loperamide therapy.</li></ul><p>&nbsp;</p><p>Loperamide should not be given prophylactically, even in patients who experienced delayed diarrhoea at previous cycles.</p><p>&nbsp;</p><p>In patients who experienced severe diarrhoea, a reduction in dose is recommended for subsequent cycles (see section 4.2).</p><p>&nbsp;</p><p><strong>Haematology</strong></p><p>In clinical studies, the frequency of NCI CTC Grade 3 and 4 neutropenia has been significantly higher in patients who received previous pelvic/abdominal irradiation than in those who had not received such irradiation. Patients with baseline serum total bilirubin levels of 1.0 mg/dl or more have also had a significantly greater likelihood of experiencing first-cycle Grade 3 or 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dl.</p><p>&nbsp;</p><p>Weekly monitoring of complete blood cell counts is recommended during Irinotecan Jazeera treatment. Patients should be aware of the risk of neutropenia and the significance of fever. Febrile neutropenia (temperature &gt; 38&deg;C and neutrophil count &le; 1,000 cells/mm<sup>3</sup>) should be urgently treated in the hospital with broad-spectrum intravenous antibiotics.</p><p>&nbsp;</p><p>In patients who experienced severe haematological events, a dose reduction is recommended for subsequent administration (see section 4.2).</p><p>&nbsp;</p><p>There is an increased risk of infections and haematological toxicity in patients with severe diarrhoea. In patients with severe diarrhoea, complete blood cell counts should be performed.</p><p>&nbsp;</p><p><strong>Patients with reduced UGT1A1 activity</strong></p><p>Patients that are UGT1A1 poor metabolisers, such as patients with Gilbert&#39;s syndrome (e.g. homozygous for UGT1A1*28 or *6 variants) are at increased risk for severe neutropenia and diarrhoea following irinotecan treatment. This risk increases with the irinotecan dose level.</p><p>Although a precise dose reduction in starting dose has not been established, a reduced irinotecan starting dose should be considered for patients that are UGT1A1 poor metabolisers, especially patients who are administered doses &gt; 180 mg/m2&nbsp;or frail patients. Consideration should be given to applicable clinical guidelines for dose recommendations in this patient population. Subsequent doses may be increased based on individual patient tolerance to treatment.</p><p>&nbsp;</p><p>UGT1A1 genotyping can be used to identify patients at increased risk of severe neutropenia and diarrhoea, however the clinical utility of pre-treatment genotyping is uncertain, since UGT1A1 polymorphism does not account for all the toxicity seen from irinotecan therapy (see section 5.2).</p><p>&nbsp;</p><p><strong>Liver impairment</strong></p><p>Liver function tests should be performed at baseline and before each cycle.</p><p>&nbsp;</p><p>Weekly monitoring of complete blood counts should be conducted in patients with bilirubin ranging from 1.5 to 3 times the ULN, due to decrease of the clearance of irinotecan (see section 5.2) and thus increasing the risk of hematotoxicity in this population. For patients with a bilirubin &gt; 3 times the ULN (see section 4.3).</p><p>&nbsp;</p><p><strong>Nausea and vomiting</strong></p><p>A prophylactic treatment with antiemetics is recommended before each treatment with Irinotecan. Nausea and vomiting have been frequently reported. Patients with vomiting associated with delayed diarrhoea should be hospitalised as soon as possible for treatment.</p><p>&nbsp;</p><p><strong>Acute cholinergic syndrome</strong></p><p>If acute cholinergic syndrome appears (defined as early diarrhoea and various other signs and symptoms such as sweating, abdominal cramping, myosis and salivation), atropine sulfate (0.25 mg subcutaneously) should be administered unless clinically contraindicated (see section 4.8).</p><p>&nbsp;</p><p>These symptoms may be observed during or shortly after infusion of irinotecan, are thought to be related to the anticholinesterase activity of the irinotecan parent compound, and are expected to occur more frequently with higher irinotecan doses.</p><p>&nbsp;</p><p>Caution should be exercised in patients with asthma. In patients who experienced an acute and severe cholinergic syndrome, the use of prophylactic atropine sulfate is recommended with subsequent doses of Irinotecan Jazeera.</p><p>&nbsp;</p><p><strong>Respiratory disorders</strong></p><p>Interstitial lung disease presenting as lung infiltration is uncommon during irinotecan therapy. Interstitial lung disease can be fatal. Risk factors possibly associated with the development of interstitial lung disease include the use of pneumotoxic medicinal products, radiation therapy and colony stimulating factors. Patients with risk factors should be closely monitored for respiratory symptoms before and during irinotecan therapy.</p><p>&nbsp;</p><p><strong>Extravasation</strong></p><p>While irinotecan is not a known vesicant, care should be taken to avoid extravasation and the infusion site should be monitored for signs of inflammation. Should extravasation occur, flushing the site and application of ice is recommended.</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>Due to the greater frequency of decreased biological functions, in particular hepatic function, in elderly patients, dose selection with Irinotecan Jazeera should be cautious in this population (see section 4.2).</p><p>&nbsp;</p><p><strong>Chronic inflammatory bowel disease and/or bowel obstruction</strong></p><p>Patients must not be treated with Irinotecan Jazeera until resolution of the bowel obstruction (see section 4.3).</p><p>&nbsp;</p><p><strong>Renal function</strong></p><p>Increases in serum creatinine or blood urea nitrogen have been observed. There have been cases of acute renal failure. These events have generally been attributed to complications of infection or to dehydration related to nausea, vomiting, or diarrhoea. Rare instances of renal dysfunction due to tumour lysis syndrome have also been reported.</p><p>&nbsp;</p><p><strong>Irradiation therapy</strong></p><p>Patients who have previously received pelvic/abdominal irradiation are at increased risk of myelosuppression following the administration of irinotecan. Physicians should use caution in treating patients with extensive prior irradiation (e.g. &gt; 25% of bone marrow irradiated and within 6 weeks prior to start of treatment with irinotecan). Dosing adjustment may apply to this population (see section 4.2).</p><p>&nbsp;</p><p><strong>Cardiac disorders</strong></p><p>Myocardial ischaemic events have been observed following irinotecan therapy predominately in patients with underlying cardiac disease, other known risk factors for cardiac disease, or previous cytotoxic chemotherapy (see section 4.8).</p><p>&nbsp;</p><p>Consequently, patients with known risk factors should be closely monitored, and action should be taken to try to minimize all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia).</p><p>&nbsp;</p><p><strong>Vascular disorders</strong></p><p>Irinotecan has been rarely associated with thromboembolic events (pulmonary embolism, venous thrombosis, and arterial thromboembolism) in patients presenting with multiple risk factors in addition to the underlying neoplasm.</p><p>&nbsp;</p><p><strong>Others</strong></p><p>Infrequent cases of renal insufficiency, hypotension or circulatory failure have been observed in patients who experienced episodes of dehydration associated with diarrhoea and/or vomiting, or sepsis.</p><p>&nbsp;</p><p><strong>Contraception in women of childbearing potential/men:</strong></p><p>Due to the potential for genotoxicity, advise female patients of reproductive potential to use highly effective contraception during treatment and for 6 months after the last dose of irinotecan.</p><p>&nbsp;</p><p>Due to the potential for genotoxicity, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of irinotecan (see section 4.6).</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>Due to the potential for adverse reactions in nursing infants, breast-feeding should be discontinued for the duration of Irinotecan Jazeera therapy (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p>Concomitant administration of irinotecan with a strong inhibitor (e.g. ketoconazole) or inducer (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, apalutamide) of CYP3A4 may alter the metabolism of irinotecan and should be avoided (see section 4.5).</p><p>&nbsp;</p><p><strong>Irinotecan Jazeera contains sorbitol and sodium</strong></p><p>Irinotecan Jazeera contains sorbitol. Each vial contains 90 mg sorbitol. Sorbitol is a source of fructose. If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects.</p><p>&nbsp;</p><p>You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.</p><p>&nbsp;</p><p>Irinotecan Jazeera contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong><em>Concomitant use contraindicated (see section 4.3)</em></strong></p><p style="text-align:justify"><strong>Saint John&#39;s Wort</strong>:&nbsp;Decrease in the active metabolite of irinotecan, SN-38, plasma levels. In a small pharmacokinetic study (n=5), in which irinotecan 350 mg/m2&nbsp;was co-administered with St. John&#39;s Wort (Hypericum perforatum)&nbsp;900 mg, a 42% decrease in the active metabolite of irinotecan, SN-38, plasma concentrations was observed. As a result, St. John&#39;s Wort should not be administered with irinotecan.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Live attenuated vaccines</strong> (e.g. yellow fever vaccine):&nbsp;Risk of generalised reaction to vaccines, possibly fatal. Concomitant use is contraindicated during treatment with irinotecan and for 6 months following discontinuation of chemotherapy. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong><em>Concomitant use not recommended (see section 4.4)</em></strong></p><p style="text-align:justify">Concurrent administration of irinotecan with a strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) may alter the metabolism of irinotecan and should be avoided (see section 4.4):</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Strong CYP3A4 and/or UGT1A1 inducing medicinal products:</strong>&nbsp;(e.g. rifampicin, carbamazepine, phenobarbital, phenytoin or apalutamide):</p><p style="text-align:justify">Risk of reduced exposure to irinotecan, SN-38 and SN-38 glucuronide and reduced pharmacodynamic effects. Several studies have shown that concomitant administration of CYP3A4-inducing anticonvulsant medicinal products leads to reduced exposure to irinotecan, SN-38 and SN-38 glucuronide and reduced pharmacodynamic effects. The effects of such anticonvulsant medicinal products were reflected by a decrease in AUC of SN-38 and SN-38G by 50% or more. In addition to induction of CYP3A4 enzymes, enhanced glucuronidation and enhanced biliary excretion may play a role in reducing exposure to irinotecan and its metabolites. Additionally, with phenytoin: Risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption by cytotoxic medicinal products.</p><p style="text-align:justify"><strong>Strong CYP3A4 inhibitors:</strong>&nbsp;(e.g. ketoconazole, itraconazole, voriconazole, posaconazole, protease inhibitors, clarithromycine, erythromycine, telithromycine):</p><p style="text-align:justify">A study has shown that the co-administration of ketoconazole resulted in a decrease in the AUC of APC of 87% and in an increase in the AUC of SN-38 of 109% in comparison to irinotecan given alone.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>UGT1A1 inhibitors:</strong>&nbsp;(e.g. atazanavir, ketoconazole, regorafenib)</p><p style="text-align:justify">Risk to increase systemic exposure to SN-38, the active metabolite of irinotecan. Physicians should take this into consideration if the combination is unavoidable.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Other CYP3A4 inhibitors</strong>: (e.g. crizotinib, idelalisib)</p><p style="text-align:justify">Risk of increase in irinotecan toxicity, due to a decrease in irinotecan metabolism by crizotinib or idelalisib.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong><em>Caution for use</em></strong></p><p style="text-align:justify"><strong>Vitamin K antagonists:&nbsp;</strong>Increased risk of haemorrhage and thrombotic events in tumoral diseases. If vitamin K antagonist are indicated, an increased frequency in the monitoring of INR (International Normalised Ratio) is required.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong><em>Concomitant use to take into consideration</em></strong></p><p style="text-align:justify"><strong>Immunodepressant agents:</strong>&nbsp;(e.g. ciclosporine, tacrolimus): Excessive immunosuppression with risk of lymphoproliferation.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Neuromuscular blocking agents:</strong>&nbsp;Interaction between irinotecan and neuromuscular blocking agents cannot be ruled out. Since Irinotecan Jazeera<strong> </strong>has anticholinesterase activity, medicinal products with anticholinesterase activity may prolong the neuromuscular blocking effects of suxamethonium and the neuromuscular blockade of non-depolarising medicinal products may be antagonised.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong><em>Other combinations</em></strong></p><p style="text-align:justify"><strong>5-fluorouracil/folinic acid:&nbsp;</strong>Coadministration of 5-fluorouracil/folinic acid in the combination regimen does not change the pharmacokinetics of irinotecan.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Bevacizumab:&nbsp;</strong>Results from a dedicated drug-drug interaction trial demonstrated no significant effect of bevacizumab on the pharmacokinetics of irinotecan and its active metabolite SN-38. However, this does not preclude any increase of toxicities due to their pharmacological properties.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Cetuximab:&nbsp;</strong>There is no evidence that the safety profile of irinotecan is influenced by cetuximab or vice versa.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Antineoplastic agents (including flucytosine as a prodrug for 5-fluorouracil):</strong>&nbsp;Adverse effects of irinotecan, such as myelosuppression, may be exacerbated by other antineoplastic agents having a similar adverse-effect profile.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Contraception</strong></p><p style="text-align:justify">Due to the potential for genotoxicity, advise female patients of reproductive potential to use highly effective contraception during treatment and for 6 months after the last dose of irinotecan (see section 4.4).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Due to the potential for genotoxicity, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of irinotecan (see section 4.4).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Pregnancy</strong></p><p style="text-align:justify">There are limited data from the use of irinotecan in pregnant women. Irinotecan has been shown to be embryotoxic and teratogenic in animals (see section 5.3). Therefore, based on results from animal studies and the mechanism of action of irinotecan, Irinotecan should not be used during pregnancy unless clearly necessary.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Women of childbearing potential should not be started on irinotecan until pregnancy is excluded. Pregnancy should be avoided if either partner is receiving irinotecan.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Breast-feeding</strong></p><p style="text-align:justify">The available data are limited but suggested that irinotecan and its metabolite are excreted in human milk. Consequently, because of the potential for adverse reactions in nursing infants, breast-feeding should be discontinued for the duration of Irinotecan Jazeera therapy (see sections&nbsp;4.3 and 4.4).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Fertility</strong></p><p style="text-align:justify">There are no human data on the effect of irinotecan on fertility. In animals&#39; adverse effects of irinotecan on the fertility of offspring has been documented (see section 5.3).&nbsp;Prior to starting to take Irinotecan Jazeera consider advising patients on the preservation of gametes.</p><p style="text-align:justify"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Irinotecan Jazeera has moderate influence on the ability to drive and use machines. Patients should be warned about the potential for dizziness or visual disturbances which may occur within 24 hours following the administration of irinotecan, and advised not to drive or operate machinery if these symptoms occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical studies</strong></p><p>Adverse reaction data have been extensively collected from studies in metastatic colorectal cancer; the frequencies are presented below. The adverse reactions for other indications are expected to be similar to those for colorectal cancer.</p><p>&nbsp;</p><p>The most common (&ge;1/10), dose-limiting adverse reactions of irinotecan are delayed diarrhoea (occurring more than 24 hours after administration) and blood disorders including neutropenia, anaemia and thrombocytopenia.</p><p>&nbsp;</p><p>Neutropenia is a dose-limiting toxic effect. Neutropenia was reversible and not cumulative; the median day to nadir was 8 days whatever the use in monotherapy or in combination therapy.</p><p>Very commonly severe transient acute cholinergic syndrome was observed.</p><p>&nbsp;</p><p>The main symptoms were defined as early diarrhoea and various other symptoms such as abdominal pain, sweating, myosis and increased salivation occurring during or within the first 24 hours after the infusion of Irinotecan. These symptoms disappear after atropine administration (see section 4.4).</p><p>&nbsp;</p><p><strong>Monotherapy</strong></p><p>The following adverse reactions considered to be possibly or probably related to the administration of Irinotecan have been reported from 765 patients at the recommended dose of 350 mg/m<sup>2</sup>&nbsp;in monotherapy. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), and very rare (&lt; 1/10,000).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Adverse Reactions Reported with Irinotecan in Monotherapy (350 mg/m<sup>2</sup>&nbsp;every 3 weeks schedule)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category</strong></p></td><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Infection</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Febrile neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cholinergic syndrome</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Alopecia (reversible)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Mucosal inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Transaminases (ALT and AST) increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Description of selected adverse reactions (monotherapy)</strong></p><p><strong>Severe diarrhoea</strong>&nbsp;was observed in 20% of patients who follow recommendations for the management of diarrhoea. Of the evaluable cycles, 14% have severe diarrhoea. The median time of onset of the first liquid stool was on day 5 after the infusion of Irinotecan.</p><p>&nbsp;</p><p><strong>Nausea and vomiting</strong>&nbsp;were severe in approximately 10% of patients treated with antiemetics.</p><p>&nbsp;</p><p><strong>Constipation</strong>&nbsp;has been observed in less than 10% of patients.</p><p>&nbsp;</p><p><strong>Neutropenia</strong>&nbsp;was observed in 78.7% of patients and was severe (neutrophil count &lt; 500 cells/mm3) in 22.6% of patients. Of the evaluable cycles, 18% had a neutrophil count below 1,000 cells/mm<sup>3</sup>&nbsp;including 7.6% with a neutrophil count &lt; 500 cells/mm<sup>3</sup>.</p><p>&nbsp;</p><p>Total recovery was usually reached by day 22.</p><p>&nbsp;</p><p><strong>Febrile neutropenia</strong>&nbsp;was reported in 6.2% of patients and in 1.7% of cycles.</p><p>&nbsp;</p><p><strong>Infections</strong>&nbsp;occurred in about 10.3% of patients (2.5% of cycles) and were associated with severe neutropenia in about 5.3% of patients (1.1% of cycles), and resulted in death in 2 cases.</p><p>&nbsp;</p><p><strong>Anaemia</strong>&nbsp;was reported in about 58.7% of patients (8% with haemoglobin &lt; 8 g/dl and 0.9% with haemoglobin &lt; 6.5 g/dl).</p><p>&nbsp;</p><p><strong>Thrombocytopenia</strong>&nbsp;(&lt; 100,000 cells/mm<sup>3</sup>) was observed in 7.4 % of patients and 1.8% of cycles with 0.9% with platelets count &le; 50,000 cells/mm3 and 0.2% of cycles.</p><p>&nbsp;</p><p>Nearly all the patients showed a recovery by day 22.</p><p>&nbsp;</p><p><strong>Acute cholinergic syndrome&nbsp;</strong>Severe transient acute cholinergic syndrome was observed in 9 % of patients treated in monotherapy.</p><p><strong>&nbsp;</strong></p><p><strong>Asthenia</strong>&nbsp;was severe in less than 10 % of patients treated in monotherapy. The causal relationship to Irinotecan has not been clearly established.</p><p>&nbsp;</p><p><strong>Pyrexia&nbsp;</strong>in the absence of infection and without concomitant severe neutropenia, occurred in 12% of patients treated in monotherapy.</p><p>&nbsp;</p><p><strong>Laboratory tests&nbsp;</strong>Transient and mild to moderate increases in serum levels of either transaminases, alkaline phosphatase or bilirubin were observed in 9.2%, 8.1% and 1.8% of the patients, respectively, in the absence of progressive liver metastasis.</p><p>&nbsp;</p><p>Transient and mild to moderate increases of serum levels of creatinine have been observed in 7.3 % of the patients.</p><p>&nbsp;</p><p><strong>Combination therapy</strong></p><p>Adverse reactions detailed in this section refer to irinotecan.</p><p>&nbsp;</p><p>There is no evidence that the safety profile of irinotecan is influenced by cetuximab or&nbsp;<em>vice versa</em>. In combination with cetuximab, additional reported adverse reactions were those expected with cetuximab (such as dermatitis acneiform 88%). For information on adverse reactions on irinotecan in combination with cetuximab, also refer to their respective summary of product characteristics.</p><p>&nbsp;</p><p>Adverse drug reactions reported in patients treated with capecitabine in combination with irinotecan in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy include:&nbsp;<em>Very common, all grade adverse drug reactions</em>: thrombosis/embolism;&nbsp;<em>Common, all grade adverse drug reactions:&nbsp;</em>hypersensitivity, myocardial ischaemia/infarction;&nbsp;<em>Common, Grade 3 and Grade 4 adverse drug reactions</em>: febrile neutropenia. For complete information on adverse reactions of capecitabine, refer to the capecitabine summary product of characteristics.</p><p>&nbsp;</p><p>Grade 3 and Grade 4 adverse drug reactions reported in patients treated with capecitabine in combination with irinotecan and bevacizumab in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy include:&nbsp;<em>Common, Grade 3 and Grade 4 adverse drug reactions:&nbsp;</em>neutropenia, thrombosis/embolism, hypertension, and myocardial ischemia/infarction. For complete information on adverse reactions of capecitabine and bevacizumab, refer to the respective capecitabine and bevacizumab summary of product characteristics.</p><p>&nbsp;</p><p>Grade 3 hypertension was the principal significant risk involved with the addition of bevacizumab to bolus CAMPTO/5-FU/FA. In addition, there was a small increase in the Grade 3/4 chemotherapy adverse events of diarrhoea and leukopenia with this regimen compared to patients receiving bolus CAMPTO/5-FU/FA alone. For other information on adverse reactions in combination with bevacizumab, refer to the bevacizumab summary of product characteristics.</p><p>&nbsp;</p><p>CAMPTO has been studied in combination with 5-FU and FA for metastatic colorectal cancer.</p><p>Safety data of adverse reactions from clinical studies demonstrate very commonly observed NCI Grade 3 or 4 possibly or probably-related adverse events in the blood and the lymphatic system disorders, gastrointestinal disorders, and skin and subcutaneous tissue disorders MedDRA System Organ Classes.</p><p>&nbsp;</p><p>The following adverse reactions considered to be possibly or probably related to the administration of CAMPTO have been reported from 145 patients treated by CAMPTO in combination therapy with 5FU/FA in every 2 weeks schedule at the recommended dose of 180 mg/m<sup>2</sup>.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Adverse Reactions Reported with Irinotecan in Combination Therapy (180 mg/m<sup>2</sup>&nbsp;every 2 weeks schedule)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category</strong></p></td><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Infection</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Febrile neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cholinergic syndrome</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Alopecia (reversible)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Mucosal inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Transaminases (ALT and AST) increased</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Description of selected adverse reactions (combination therapy)</strong></p><p><strong>Severe diarrhoea</strong>&nbsp;was observed in 13.1 % of patients who follow recommendations for the management of diarrhoea. Of the evaluable cycles, 3.9 % have a severe diarrhoea.</p><p>&nbsp;</p><p>A lower incidence of severe&nbsp;<strong>nausea and vomiting</strong>&nbsp;was observed (2.1% and 2.8% of patients respectively).</p><p>&nbsp;</p><p><strong>Constipation</strong>&nbsp;relative to Irinotecan and/or loperamide has been observed in 3.4 % of patients.</p><p>&nbsp;</p><p><strong>Neutropenia</strong>&nbsp;was observed in 82.5% of patients and was severe (neutrophil count &lt; 500 cells/mm3) in 9.8% of patients. Of the evaluable cycles, 67.3% had a neutrophil count below 1,000 cells/mm<sup>3</sup>&nbsp;including 2.7% with a neutrophil count &lt; 500 cells/mm<sup>3</sup>. Total recovery was usually reached within 7-8 days.</p><p>&nbsp;</p><p><strong>Febrile neutropenia</strong>&nbsp;was reported in 3.4% of patients and in 0.9% of cycles.</p><p>&nbsp;</p><p><strong>Infections</strong>&nbsp;occurred in about 2% of patients (0.5% of cycles) and were associated with severe neutropenia in about 2.1% of patients (0.5% of cycles), and resulted in death in 1 case.</p><p>&nbsp;</p><p><strong>Anaemia</strong>&nbsp;was reported in 97.2% of patients (2.1% with haemoglobin &lt; 8 g/dl).</p><p>&nbsp;</p><p><strong>Thrombocytopenia</strong>&nbsp;(&lt; 100,000 cells/mm<sup>3</sup>) was observed in 32.6% of patients and 21.8% of cycles. No severe thrombocytopenia (&lt; 50,000 cells/mm<sup>3</sup>) has been observed.</p><p>&nbsp;</p><p><strong>Acute cholinergic syndrome&nbsp;</strong>Severe transient acute cholinergic syndrome was observed in 1.4 % of patients treated in combination therapy.</p><p>&nbsp;</p><p><strong>Asthenia</strong>&nbsp;was severe in 6.2 % of patients treated in combination therapy. The causal relationship to Irinotecan has not been clearly established.</p><p>&nbsp;</p><p><strong>Pyrexia in the absence of infection</strong>&nbsp;and without concomitant severe neutropenia, occurred in 6.2 % of patients treated in combination therapy.</p><p>&nbsp;</p><p><strong>Laboratory tests&nbsp;</strong>Transient serum levels (Grades 1 and 2) of either SGPT, SGOT, alkaline phosphatase or bilirubin were observed in 15%, 11%, 11% and 10% of the patients, respectively, in the absence of progressive liver metastasis. Transient Grade 3 were observed in 0%, 0%, 0% and 1% of the patients, respectively. No Grade 4 was observed.</p><p>&nbsp;</p><p>Increases of amylase and/or lipase have been very rarely reported.</p><p>&nbsp;</p><p>Rare cases of hypokalaemia and hyponatraemia mostly related with diarrhoea and vomiting have been reported.</p><p>&nbsp;</p><p><strong>Other adverse events reported in clinical studies with the weekly regimen for irinotecan</strong></p><p>The following additional drug-related events have been reported in clinical studies with irinotecan: pain, sepsis, anorectal disorder, GI candida infection, hypomagnesaemia, rash, skin signs, gait disturbance, confusion, headache, syncope, flushing, bradycardia, urinary tract infection, breast pain, gamma-glutamyltransferase increased, extravasation, and tumour lysis syndrome, cardiovascular disorders (angina pectoris, cardiac arrest, myocardial infarction, myocardial ischaemia, peripheral vascular disorder, vascular disorder), and thromboembolic events (arterial thrombosis, cerebral infarction, cerebrovascular accident, deep vein thrombosis, peripheral embolism , pulmonary embolism, thrombophlebitis, thrombosis, and sudden death) (see section 4.4).</p><p>&nbsp;</p><p><strong>Post-marketing surveillance</strong></p><p>Frequencies from post-marketing surveillance are not known (cannot be estimated from available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&bull; Pseudomembranous colitis one of which has been documented bacteriologically (<em>Clostridium difficile</em>)</p><p>&bull; Sepsis</p><p>&bull; Fungal infections*</p><p>&bull; Viral infections<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&bull; Thrombocytopenia with antiplatelet antibodies</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&bull; Hypersensitivity</p><p>&bull; Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&bull; Dehydration (due to diarrhoea and vomiting)</p><p>&bull; Hypovolaemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&bull; Speech disorder generally transient in nature, in some cases, the event was attributed to the cholinergic syndrome observed during or shortly after infusion of irinotecan</p><p>&bull; Paraesthesia</p><p>&bull; Muscular contractions involuntary</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&bull; Hypertension (during or after infusion)</p><p>&bull; Cardio circulatory failure<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&bull; Hypotension<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&bull; Interstitial lung disease presenting as lung infiltration is uncommon during irinotecan therapy; early effects such as dyspnoea have been reported (see section 4.4).</p><p>&bull; Dyspnoea (see section 4.4)</p><p>&bull; Hiccups</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&bull; Intestinal obstruction</p><p>&bull; Ileus: cases of ileus without preceding colitis have also been reported</p><p>&bull; Megacolon</p><p>&bull; Gastrointestinal haemorrhage</p><p>&bull; Colitis; in some cases, colitis was complicated by ulceration, bleeding, ileus, or infection.</p><p>&bull; Typhlitis</p><p>&bull; Colitis ischaemic</p><p>&bull; Colitis ulcerative</p><p>&bull; Symptomatic or asymptomatic pancreatic enzymes increased</p><p>&bull; Intestinal perforation</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&bull; Steatohepatitis</p><p>&bull; Hepatic steatosis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&bull; Skin reaction</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&bull; Cramps</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&bull; Renal impairment and acute renal failure generally in patients who become infected and/or volume depleted from severe gastrointestinal toxicities<sup>&Dagger;</sup></p><p>&bull; Renal insufficiency<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&bull; Infusion site reaction</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&bull; Amylase increased</p><p>&bull; Lipase increased</p><p>&bull; Hypokalaemia</p><p>&bull; Hyponatraemia mostly related with diarrhoea and vomiting</p><p>&bull; Transaminases increased (i.e. AST and ALT) in the absence of progressive liver metastasis have been very rarely reported.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*e.g. Pneumocystis jirovecii pneumonia, bronchopulmonary aspergillosis, systemic candida.</p><p><sup>&dagger;</sup>e.g. Herpes zoster, influenza, hepatitis B reactivation, cytomegalovirus colitis.</p><p><sup>&Dagger;</sup>Infrequen<u>t</u>&nbsp;cases of renal insufficiency, hypotension or cardio circulatory failure have been observed in patients who experienced episodes of dehydration associated with diarrhoea and/or vomiting, or sepsis.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting systems applied at their countries via:</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Symptoms</strong></p><p style="text-align:justify">There have been reports of overdosage at doses up to approximately twice the recommended therapeutic dose, which may be fatal. The most significant adverse reactions reported were severe neutropenia and severe diarrhoea.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Management</strong></p><p style="text-align:justify">There is no known antidote for Irinotican. Maximum supportive care should be instituted to prevent dehydration due to diarrhoea and to treat any infectious complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: Cytostatic topoisomerase I inhibitor. ATC Code: L01XX19</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong><em>Mechanism of action</em></strong></p><p style="text-align:justify"><strong>Experimental data:</strong></p><p style="text-align:justify">Irinotecan is a semi-synthetic derivative of camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of DNA topoisomerase I. It is metabolised by carboxylesterase in most tissues to SN-38, which was found to be more active than irinotecan in purified topoisomerase I and more cytotoxic than irinotecan against several murine and human tumour cell lines. The inhibition of DNA topoisomerase I by irinotecan or SN-38 induces single-strand DNA lesions which blocks the DNA replication fork and are responsible for the cytotoxicity. This cytotoxic activity was found time-dependent and was specific to the S phase.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>In vitro</em>, irinotecan and SN-38 were not found to be significantly recognised by the P -glycoprotein MDR, and displays cytotoxic activities against doxorubicin and vinblastine resistant cell lines.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Furthermore, irinotecan has a broad antitumor activity&nbsp;<em>in vivo</em>&nbsp;against murine tumour models (P03 pancreatic ductal adenocarcinoma, MA16/C mammary adenocarcinoma, C38 and C51 colon adenocarcinomas) and against human xenografts (Co-4 colon adenocarcinoma, Mx-1 mammary adenocarcinoma, ST-15 and SC-16 gastric adenocarcinomas). Irinotecan is also active against tumours expressing the P-glycoprotein MDR (vincristine- and doxorubicin-resistant P388 leukaemias).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Beside the antitumor activity of irinotecan, the most relevant pharmacological effect of irinotecan is the inhibition of acetylcholinesterase.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Clinical data:</strong></p><p style="text-align:justify"><u>In combination therapy for the first-line treatment of metastatic colorectal carcinoma</u></p><p style="text-align:justify"><em>In combination therapy with Folinic Acid and 5-Fluorouracil</em></p><p style="text-align:justify">A phase III study was performed in 385 previously untreated metastatic colorectal cancer patients treated with either every 2 weeks schedule (see section 4.2) or weekly schedule regimens. In the every 2 weeks schedule, on day 1, the administration of irinotecan at 180 mg/m<sup>2</sup>&nbsp;once every 2 weeks is followed by infusion with folinic acid (200 mg/m<sup>2</sup>&nbsp;over a 2-hour intravenous infusion) and 5-fluorouracil (400 mg/m<sup>2</sup>&nbsp;as an intravenous bolus, followed by 600 mg/m<sup>2</sup>&nbsp;over a 22-hour intravenous infusion). On day 2, folinic acid and 5-fluorouracil are administered at the same doses and schedules. In the weekly schedule, the administration of irinotecan at 80 mg/m<sup>2</sup>&nbsp;is followed by infusion with folinic acid (500 mg/m<sup>2</sup>&nbsp;over a 2-hour intravenous infusion) and then by 5-fluorouracil (2300 mg/m<sup>2</sup>&nbsp;over a 24-hour intravenous infusion) over 6 weeks.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In the combination therapy trial with the 2 regimens described above, the efficacy of irinotecan was evaluated in 198 treated patients:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">Combined regimens</p><p style="text-align:justify">(n=198)</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">Weekly schedule</p><p style="text-align:justify">(n=50)</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">Every 2 weeks schedule</p><p style="text-align:justify">(n=148)</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Irinotecan +5FU/FA</p></td><td style="vertical-align:top"><p style="text-align:justify">5FU/FA</p></td><td style="vertical-align:top"><p style="text-align:justify">Irinotecan +5FU/FA</p></td><td style="vertical-align:top"><p style="text-align:justify">5FU/FA</p></td><td style="vertical-align:top"><p style="text-align:justify">Irinotecan +5FU/FA</p></td><td style="vertical-align:top"><p style="text-align:justify">5FU/FA</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Response rate (%)</p></td><td style="vertical-align:top"><p style="text-align:justify">40.8 *</p></td><td style="vertical-align:top"><p style="text-align:justify">23.1 *</p></td><td style="vertical-align:top"><p style="text-align:justify">51.2 *</p></td><td style="vertical-align:top"><p style="text-align:justify">28.6 *</p></td><td style="vertical-align:top"><p style="text-align:justify">37.5 *</p></td><td style="vertical-align:top"><p style="text-align:justify">21.6 *</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">p-value</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p&lt;0.001</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p=0.045</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p=0.005</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Median time to progression (months)</p></td><td style="vertical-align:top"><p style="text-align:justify">6.7</p></td><td style="vertical-align:top"><p style="text-align:justify">4.4</p></td><td style="vertical-align:top"><p style="text-align:justify">7.2</p></td><td style="vertical-align:top"><p style="text-align:justify">6.5</p></td><td style="vertical-align:top"><p style="text-align:justify">6.5</p></td><td style="vertical-align:top"><p style="text-align:justify">3.7</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">p-value</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p&lt;0.001</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">NS</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p=0.001</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Median duration of response (months)</p></td><td style="vertical-align:top"><p style="text-align:justify">9.3</p></td><td style="vertical-align:top"><p style="text-align:justify">8.8</p></td><td style="vertical-align:top"><p style="text-align:justify">8.9</p></td><td style="vertical-align:top"><p style="text-align:justify">6.7</p></td><td style="vertical-align:top"><p style="text-align:justify">9.3</p></td><td style="vertical-align:top"><p style="text-align:justify">9.5</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">p-value</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">NS</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p=0.043</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">NS</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Median duration of response and stabilisation (months)</p></td><td style="vertical-align:top"><p style="text-align:justify">8.6</p></td><td style="vertical-align:top"><p style="text-align:justify">6.2</p></td><td style="vertical-align:top"><p style="text-align:justify">8.3</p></td><td style="vertical-align:top"><p style="text-align:justify">6.7</p></td><td style="vertical-align:top"><p style="text-align:justify">8.5</p></td><td style="vertical-align:top"><p style="text-align:justify">5.6</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">p-value</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p&lt;0.001</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">NS</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p=0.003</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Median time to treatment failure (months)</p></td><td style="vertical-align:top"><p style="text-align:justify">5.3</p></td><td style="vertical-align:top"><p style="text-align:justify">3.8</p></td><td style="vertical-align:top"><p style="text-align:justify">5.4</p></td><td style="vertical-align:top"><p style="text-align:justify">5.0</p></td><td style="vertical-align:top"><p style="text-align:justify">5.1</p></td><td style="vertical-align:top"><p style="text-align:justify">3.0</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">p-value</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p=0.0014</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">NS</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Median survival (months)</p></td><td style="vertical-align:top"><p style="text-align:justify">16.8</p></td><td style="vertical-align:top"><p style="text-align:justify">14.0</p></td><td style="vertical-align:top"><p style="text-align:justify">19.2</p></td><td style="vertical-align:top"><p style="text-align:justify">14.1</p></td><td style="vertical-align:top"><p style="text-align:justify">15.6</p></td><td style="vertical-align:top"><p style="text-align:justify">13.0</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">p-value</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p=0.028</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">NS</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify">p=0.041</p></td></tr></tbody></table><p style="text-align:justify">5FU: 5-fluorouracil</p><p style="text-align:justify">FA: folinic acid</p><p style="text-align:justify">NS: Non Significant</p><p style="text-align:justify">*As per protocol population analysis</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In the weekly schedule, the incidence of severe diarrhoea was 44.4% in patients treated by irinotecan in combination with 5FU/FA and 25.6% in patients treated by 5FU/FA alone. The incidence of severe neutropenia (neutrophil count &lt; 500 cells/mm<sup>3</sup>) was 5.8% in patients treated by irinotecan in combination with 5FU/FA and in 2.4% in patients treated by 5FU/FA alone.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Additionally, median time to definitive performance status deterioration was significantly longer in irinotecan combination group than in 5FU/FA alone group (p=0.046).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Quality of life was assessed in this phase III study using the EORTC QLQ-C30 questionnaire. Time to definitive deterioration constantly occurred later in the irinotecan groups. The evolution of the Global Health Status/Quality of life was slightly better in irinotecan combination group although not significant, showing that efficacy of irinotecan in combination could be reached without affecting the quality of life.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>In combination therapy with bevacizumab</em></p><p style="text-align:justify">A phase III randomised, double-blind, active-controlled clinical trial evaluated bevacizumab in combination with irinotecan/5FU/FA as first-line treatment for metastatic carcinoma of the colon or rectum (Study AVF2107g). The addition of bevacizumab to the combination of irinotecan /5FU/FA resulted in a statistically significant increase in overall survival. The clinical benefit, as measured by overall survival, was seen in all pre-specified patient subgroups, including those defined by age, sex, performance status, location of primary tumour, number of organs involved, and duration of metastatic disease. Refer also to the bevacizumab summary of product characteristics. The efficacy results of Study AVF2107g are summarized in the table below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:justify"><strong>AVF2107g</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center"><strong>Arm 1</strong></p><p style="text-align:center"><strong>Irinotecan/5FU/FA + Placebo</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Arm 2</strong></p><p style="text-align:center"><strong>Irinotecan/5FU/FA + Avastin<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Number of Patients</p></td><td style="vertical-align:top"><p style="text-align:center">411</p></td><td style="vertical-align:top"><p style="text-align:center">402</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Overall survival</p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="text-align:justify; vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Median time (months)</p></td><td style="vertical-align:top"><p style="text-align:center">15.6</p></td><td style="vertical-align:top"><p style="text-align:center">20.3</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p style="text-align:center">14.29 &ndash; 16.99</p></td><td style="vertical-align:top"><p style="text-align:center">18.46 &ndash; 24.18</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Hazard ratio<sup>b</sup></p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p style="text-align:center">0.660</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p style="text-align:center">0.00004</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Progression-free survival</p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="text-align:justify; vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Median time (months)</p></td><td style="vertical-align:top"><p style="text-align:center">6.2</p></td><td style="vertical-align:top"><p style="text-align:center">10.6</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Hazard ratio</p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p style="text-align:center">0.54</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">p-value</p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p style="text-align:center">&lt; 0.0001</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Overall response rate</p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="text-align:justify; vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Rate (%)</p></td><td style="vertical-align:top"><p style="text-align:center">34.8</p></td><td style="vertical-align:top"><p style="text-align:center">44.8</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">95% CI</p></td><td style="vertical-align:top"><p style="text-align:center">30.2 &ndash; 39.6</p></td><td style="vertical-align:top"><p style="text-align:center">39.9 &ndash; 49.8</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">p-value</p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p style="text-align:center">0.0036</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Duration of response</p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="text-align:justify; vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Median time (months)</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>10.4</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">25&ndash;75 percentile (months)</p></td><td style="vertical-align:top"><p style="text-align:justify">4.7 &ndash; 11.8</p></td><td style="vertical-align:top"><p style="text-align:justify">6.7 &ndash; 15.0</p></td></tr></tbody></table><p style="text-align:justify"><sup>a</sup>5 mg/kg every 2 weeks.</p><p style="text-align:justify"><sup>b</sup>Relative to control arm.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>In combination therapy with cetuximab:</em></p><p style="text-align:justify">EMR 62 202-013: This randomised study in patients with metastatic colorectal cancer who had not received prior treatment for metastatic disease compared the combination of cetuximab and irinotecan plus infusional 5-fluorouracil/folinic acid (5-FU/FA) (599 patients) to the same chemotherapy alone (599 patients). The proportion of patients with KRAS wild-type tumours from the patient populations evaluable for KRAS status comprised 64%.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The efficacy data generated in this study are summarised in the table below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center"><strong>Overall population</strong></p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center"><strong>KRAS wild-type population</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Variable/statistic</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Cetuximab plus FOLFIRI</strong></p><p style="text-align:center"><strong>(N=599)</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>FOLFIRI</strong></p><p style="text-align:center"><strong>(N=599)</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Cetuximab plus FOLFIRI</strong></p><p style="text-align:center"><strong>(N=172)</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>FOLFIRI</strong></p><p style="text-align:center"><strong>(N=176)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p style="text-align:justify"><strong>ORR</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">% (95%CI)</p></td><td style="vertical-align:top"><p style="text-align:center">46.9 (42.9, 51.0)</p></td><td style="vertical-align:top"><p style="text-align:center">38.7 (34.8, 42.8)</p></td><td style="vertical-align:top"><p style="text-align:center">59.3 (51.6, 66.7)</p></td><td style="vertical-align:top"><p style="text-align:center">43.2 (35.8, 50.9)</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">p-value</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center">0.0038</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center">0.0025</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>PFS</strong></p></td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="text-align:justify; vertical-align:top">&nbsp;</td><td style="text-align:justify; vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Hazard Ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center">0.85 (0.726, 0.998)</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center">0.68 (0.501, 0.934)</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">p-value</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center">0.0479</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center">0.0167</p></td></tr></tbody></table><p style="text-align:justify">CI = confidence interval, FOLFIRI = irinotecan plus infusional 5-FU/FA, ORR = objective response rate (patients with complete response or partial response), PFS = progression-free survival time</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>In combination therapy with capecitabine</em></p><p style="text-align:justify">Data from a randomised, controlled phase III study (CAIRO) support the use of capecitabine at a starting dose of 1000 mg/m<sup>2</sup>&nbsp;for 2 weeks every 3 weeks in combination with irinotecan for the first-line treatment of patients with metastatic colorectal cancer. Eight hundred twenty (820) patients were randomised to receive either sequential treatment (n=410) or combination treatment (n=410). Sequential treatment consisted of first-line treatment with capecitabine (1250 mg/m<sup>2</sup>&nbsp;twice daily for 14 days), second-line irinotecan (350 mg/m<sup>2</sup>&nbsp;on day 1), and third-line combination of capecitabine (1000 mg/m<sup>2</sup>&nbsp;twice daily for 14 days) with oxaliplatin (130 mg/m<sup>2</sup>&nbsp;on day 1). Combination treatment consisted of first-line treatment of capecitabine (1000 mg/m<sup>2</sup>&nbsp;twice daily for 14 days) combined with irinotecan (250 mg /m<sup>2</sup>&nbsp;on day 1) (XELIRI) and second-line capecitabine (1000 mg/m<sup>2</sup>&nbsp;twice daily for 14 days) plus oxaliplatin (130 mg/m<sup>2</sup>&nbsp;on day 1). All treatment cycles were administered at intervals of 3 weeks. In first-line treatment the median progression-free survival in the intent-to-treat population was 5.8 months (95%CI, 5.1 -6.2 months) for capecitabine monotherapy and 7.8 months (95%CI, 7.0-8.3 months) for XELIRI (p=0.0002).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Data from an interim analysis of a multicentre, randomised, controlled phase II study (AIO KRK 0604) support the use of capecitabine at a starting dose of 800 mg/m<sup>2</sup>&nbsp;for 2 weeks every 3 weeks in combination with irinotecan and bevacizumab for the first-line treatment of patients with metastatic colorectal cancer. One hundred fifteen (115) patients were randomised to treatment with capecitabine combined with irinotecan (XELIRI) and bevacizumab: capecitabine (800 mg/m<sup>2</sup>&nbsp;twice daily for 2 weeks followed by a 7-day rest period), irinotecan (200 mg/m<sup>2</sup>&nbsp;as a 30 minute infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks); a total of 118 patients were randomised to treatment with capecitabine combined with oxaliplatin plus bevacizumab: capecitabine (1000 mg/m<sup>2</sup>&nbsp;twice daily for two weeks followed by a 7-day rest period), oxaliplatin (130 mg/m<sup>2</sup>&nbsp;as a 2 hour infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks). Progression-free survival at 6 months in the intent-to-treat population was 80% (XELIRI plus bevacizumab) versus 74% (XELOX plus bevacizumab). Overall response rate (complete response plus partial response) was 45% (XELOX plus bevacizumab) versus 47% (XELIRI plus bevacizumab).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>In monotherapy for the second-line treatment of metastatic colorectal carcinoma:</u></p><p style="text-align:justify">Clinical phase II/III studies were performed in more than 980 patients in the every 3-week dosage schedule with metastatic colorectal cancer who failed a previous 5-FU regimen. The efficacy of irinotecan was evaluated in 765 patients with documented progression on 5-FU at study entry.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p style="text-align:center">Phase III</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p style="text-align:center">Irinotecan versus supportive care</p></td><td colspan="3" style="vertical-align:top"><p style="text-align:center">Irinotecan versus 5FU</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">Irinotecan</p><p style="text-align:center">n=183</p></td><td style="vertical-align:top"><p style="text-align:center">Supportive care</p><p style="text-align:center">n=90</p></td><td style="vertical-align:top"><p style="text-align:center">p-values</p></td><td style="vertical-align:top"><p style="text-align:center">Irinotecan</p><p style="text-align:center">n=127</p></td><td style="vertical-align:top"><p style="text-align:center">5FU</p><p style="text-align:center">n=129</p></td><td style="vertical-align:top"><p style="text-align:center">p-values</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Progression-Free Survival at 6 months (%)</p></td><td style="vertical-align:top"><p style="text-align:center">NA</p></td><td style="vertical-align:top"><p style="text-align:center">NA</p></td><td style="text-align:center; vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p style="text-align:center">33.5 *</p></td><td style="vertical-align:top"><p style="text-align:center">26.7</p></td><td style="vertical-align:top"><p style="text-align:center">p=0.03</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Survival at 12 months (%)</p></td><td style="vertical-align:top"><p style="text-align:center">36.2 *</p></td><td style="vertical-align:top"><p style="text-align:center">13.8</p></td><td style="vertical-align:top"><p style="text-align:center">p=0.0001</p></td><td style="vertical-align:top"><p style="text-align:center">44.8 *</p></td><td style="vertical-align:top"><p style="text-align:center">32.4</p></td><td style="vertical-align:top"><p style="text-align:center">p=0.0351</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">Median survival (months)</p></td><td style="vertical-align:top"><p style="text-align:center">9.2*</p></td><td style="vertical-align:top"><p style="text-align:center">6.5</p></td><td style="vertical-align:top"><p style="text-align:center">p=0.0001</p></td><td style="vertical-align:top"><p style="text-align:center">10.8*</p></td><td style="vertical-align:top"><p style="text-align:center">8.5</p></td><td style="vertical-align:top"><p style="text-align:center">p=0.0351</p></td></tr></tbody></table><p style="text-align:justify">NA=Non Applicable</p><p style="text-align:justify">*Statistically significant difference</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In phase II studies, performed on 455 patients in the every 3-week dosage schedule, the progression-free survival at 6 months was 30 % and the median survival was 9 months. The median time to progression was 18 weeks.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Additionally, non-comparative phase II studies were performed in 304 patients treated with a weekly schedule regimen, at a dose of 125 mg/m<sup>2</sup>&nbsp;administered as an intravenous infusion over 90 minutes for 4 consecutive weeks followed by 2 weeks rest. In these studies, the median time to progression was 17 weeks and median survival was 10 months. A similar safety profile has been observed in the weekly-dosage schedule in 193 patients at the starting dose of 125 mg/m<sup>2</sup>, compared to the every 3-week-dosage schedule. The median time of onset of the first liquid stool was on day 11.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>In combination with cetuximab after failure of irinotecan-including cytotoxic therapy</u></p><p style="text-align:justify">The efficacy of the combination of cetuximab with irinotecan was investigated in two clinical studies. A total of 356 patients with EGFR-expressing metastatic colorectal cancer who had recently failed irinotecan-including cytotoxic therapy and who had a minimum Karnofsky performance status of 60, but the majority of whom had a Karnofsky performance status of &ge; 80 received the combination treatment.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">EMR 62 202-007: This randomised study compared the combination of cetuximab and irinotecan (218 patients) with cetuximab monotherapy (111 patients).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">IMCL CP02-9923: This single arm open-label study investigated the combination therapy in 138 patients.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The efficacy data from these studies are summarised in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p style="text-align:justify"><u>Study</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>N</u></p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center"><u>ORR</u></p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center"><u>DCR</u></p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center"><u>PFS (months)</u></p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center"><u>OS (months)</u></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">&nbsp;</p></td><td style="text-align:center; vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p style="text-align:center"><u>n (%)</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>95% CI</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>n (%)</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>95% CI</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>Median</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>95% CI</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>Median</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>95% CI</u></p></td></tr><tr><td colspan="10" style="vertical-align:top"><p style="text-align:justify"><u>Cetuximab+ Irinotecan</u></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><u>EMR 62 202-007</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>218</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>50</u></p><p style="text-align:center"><u>(22.9)</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>17.5, 29.1</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>121</u></p><p style="text-align:center"><u>(55.5)</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>48.6, 62.2</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>4.1</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>2.8, 4.3</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>8.6</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>7.6, 9.6</u></p></td></tr><tr><td style="vertical-align:top"><p><u>IMCLCP02-9923</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>138</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>21</u></p><p style="text-align:center"><u>(15.2)</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>9.7, 22.3</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>84</u></p><p style="text-align:center"><u>(60.9)</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>52.2, 69.1</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>2.9</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>2.6, 4.1</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>8.4</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>7.2, 10.3</u></p></td></tr><tr><td colspan="10" style="vertical-align:top"><p><u>Cetuximab</u></p></td></tr><tr><td style="vertical-align:top"><p><u>EMR 62 202-007</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>111</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>12</u></p><p style="text-align:center"><u>(10.8)</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>5.7, 18.1</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>36</u></p><p style="text-align:center"><u>(32.4)</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>23.9, 42.0</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>1.5</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>1.4, 2.0</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>6.9</u></p></td><td style="vertical-align:top"><p style="text-align:center"><u>5.6, 9.1</u></p></td></tr></tbody></table><p style="text-align:justify">CI= confidence interval, DCR= disease control rate (patients with complete response, partial response, or stable disease for at least 6 weeks), ORR= objective response rate (patients with complete response or partial response), OS= overall survival time, PFS= progression-free survival.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The efficacy of the combination of cetuximab with irinotecan was superior to that of cetuximab monotherapy, in terms of objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS). In the randomised trial, no effects on overall survival were demonstrated (hazard ratio 0.91, p=0.48).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Absorption</strong></p><p style="text-align:justify">At the end of the infusion, at the recommended dose of 350 mg/m<sup>2</sup>, the mean peak plasma concentrations of irinotecan and SN-38 were 7.7 &micro;g/ml and 56 ng/ml, respectively, and the mean area under the curve (AUC) values were 34 &micro;g.h/ml and 451 ng.h/ml, respectively. A large interindividual variability in pharmacokinetic parameters is generally observed for SN-38.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Distribution</strong></p><p style="text-align:justify">The phase I study in 60 patients with a dosage regimen of a 30-minute intravenous infusion of 100 to 750 mg/m<sup>2 </sup>every three weeks, the volume of distribution at steady state (Vss): 157 L/m<sup>2</sup>.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In vitro, plasma protein binding for irinotecan and SN-38 was approximately 65% and 95%, respectively.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Biotransformation</strong></p><p style="text-align:justify">Mass balance and metabolism studies with 14C-labelled drug have shown that more than 50% of an intravenously administered dose of irinotecan is excreted as unchanged drug, with 33% in the faeces mainly via the bile and 22% in urine.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Two metabolic pathways account each for at least 12% of the dose:</p><ul><li style="text-align:justify">&nbsp;Hydrolysis by carboxylesterase into active metabolite SN-38, SN-38 is mainly eliminated by glucuronidation, and further by biliary and renal excretion (less than 0.5% of the irinotecan dose) The SN-38 glucuronite is subsequently probably hydrolysed in the intestine.</li></ul><p style="text-align:justify">&nbsp;</p><ul><li style="text-align:justify">&nbsp;Cytochrome P450 3A enzymes-dependent oxidations resulting in opening of the outer piperidine ring with formation of APC (aminopentanoic acid derivate) and NPC (primary amine derivate) (see section 4.5).</li></ul><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Unchanged irinotecan is the major entity in plasma, followed by APC, SN-38 glucuronide and SN-38. Only SN-38 has significant cytotoxic activity.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Elimination</strong></p><p style="text-align:justify">In a phase I study in 60 patients with a dosage regimen of a 30-minute intravenous infusion of 100 to 750 mg/m<sup>2</sup>&nbsp;every three weeks, irinotecan showed a biphasic or triphasic elimination profile. The mean plasma clearance was 15 L/h/m<sup>2</sup>. The mean plasma half-life of the first phase of the triphasic model was 12 minutes, of the second phase 2.5 hours, and the terminal phase half-life was 14.2 hours. SN-38 showed a biphasic elimination profile with a mean terminal elimination half-life of 13.8 hours.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Irinotecan clearance is decreased by about 40% in patients with bilirubinemia between 1.5 and 3 times the upper normal limit. In these patients a 200 mg/m<sup>2</sup>&nbsp;irinotecan dose leads to plasma drug exposure comparable to that observed at 350 mg/m<sup>2</sup>&nbsp;in cancer patients with normal liver parameters.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Linearity/non-linearity</strong></p><p style="text-align:justify">A population pharmacokinetic analysis of irinotecan has been performed in 148 patients with metastatic colorectal cancer, treated with various schedules and at different doses in phase II trials. Pharmacokinetic parameters estimated with a three compartment model were similar to those observed in phase I studies. All studies have shown that irinotecan (CPT-11) and SN-38 exposure increase proportionally with CPT-11 administered dose; their pharmacokinetics are independent of the number of previous cycles and of the administration schedule.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Pharmacokinetic/Pharmacodynamic relationship(s)</strong></p><p style="text-align:justify">The intensity of the major toxicities encountered with Irinotecan (e.g. leukoneutropenia and diarrhoea) are related to the exposure (AUC) to parent drug and metabolite SN-38. Significant correlations were observed between haematological toxicity (decrease in white blood cells and neutrophils at nadir) or diarrhoea intensity and both irinotecan and metabolite SN-38 AUC values in monotherapy.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Patients with reduced UGT1A1 activity</strong></p><p style="text-align:justify">Uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) is involved in the metabolic deactivation of SN-38, the active metabolite of irinotecan to inactive SN-38 glucuronide (SN-38G). The UGT1A1 gene is highly polymorphic, resulting in variable metabolic capacities among individuals. The most well-characterised UGT1A1 genetic variants are UGT1A1*28 and UGT1A1*6. These variants and other congenital deficiencies in UGT1A1 expression (Such as Gilbert&#39;s syndrome and Crigler-Najjar) are associated with reduced activity of this enzyme.</p><p style="text-align:justify">Patients that are UGT1A1 poor metabolisers (e.g. homozygous for UGT1A1*28 or *6 variants) are at increased risk of severe adverse reactions such as neutropenia and diarrhoea following administration of irinotecan, as a consequence of SN-38 accumulation. According to data from several meta-analyses, the risk is higher for patients receiving irinotecan doses &gt; 180 mg/m2&nbsp;(see section 4.4).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In order to identify patients at increased risk of experiencing severe neutropenia and diarrhoea, UGT1A1 genotyping can be used. Homozygous UGT1A1*28 occurs with a frequency of 8-20% in the European, African, Near Eastern and Latino population. The *6 variant is nearly absent in these populations. In the East Asian population the frequency of *28/*28 is about 1-4%, 3-8% for *6/*28 and 2-6% for *6/*6. In the Central and South Asian population the frequency of *28/*28 is around 17%, 4% for *6/*28 and 0.2% for *6/*6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Irinotecan and SN-38 have been shown to be mutagenic&nbsp;<em>in vitro</em>&nbsp;in the chromosomal aberration test on CHO-cells as well as in the&nbsp;<em>in vivo</em>&nbsp;micronucleus test in mice.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">However, they have been shown to be devoid of any mutagenic potential in the Ames test.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In rats treated once a week during 13 weeks at the maximum dose of 150 mg/m<sup>2</sup>&nbsp;(which is less than half the human recommended dose), no treatment related tumours were reported 91 weeks after the end of treatment.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Single- and repeated-dose toxicity studies with irinotecan have been carried out in mice, rats and dogs. The main toxic effects were seen in the haematopoietic and lymphatic systems. In dogs, delayed diarrhoea associated with atrophy and focal necrosis of the intestinal mucosa was reported. Alopecia was also observed in the dog.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The severity of these effects was dose-related and reversible.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Reproduction</strong></p><p style="text-align:justify">Irinotecan was teratogenic in rats and rabbits at doses below the human therapeutic dose. In rats, pups born to treated animals with external abnormalities showed a decrease in fertility. This was not seen in morphologically normal pups. In pregnant rats there was a decrease in placental weight and in the offspring a decrease in fetal viability and increase in behavioural abnormalities</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Sorbitol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Lactic acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hydrochloric acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p><p>&nbsp;</p><p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months. 

The diluted Irinotecan Jazeera solution is physically and chemically stable as a solution for infusion (9% sodium chloride solution or 5% dextrose solution) when stored in polyethylene infusion bags up to 12 hours at room temperature and for up to 24 hours at fridge conditions (2-8°C) when protected from light.  

It is recommended, however, that in order to reduce microbiological hazard, the infusion solutions should be prepared immediately prior to use and infusion commenced as soon as practicable after preparation. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For storage conditions after dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p><p>Store below 25&deg;C.</p><p>Protect from light.</p><p>Store in the original package.</p><p>After dilution: The medicine will be given to you within 24 hours of dilution. The diluted solution may have been stored at 2 to 8&deg;C in a refrigerator.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I amber glass vials sealed with grey stoppers and aluminum flip-off caps with red cover.</p><p>&nbsp;</p><p>Pack size: 1 Vial (2 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other antineoplastic agents, Irinotecan Jazeera must be prepared and handled with caution. The use of glasses, mask and gloves is required.</p><p>&nbsp;</p><p>If Irinotecan Jazeera solution or infusion solution should come into contact with the skin, wash immediately and thoroughly with soap and water. If Irinotecan Jazeera solution or infusion solution should come into contact with the mucous membranes, wash immediately with water.</p><p><strong>&nbsp;</strong></p><p><strong>Preparation for the intravenous infusion administration:</strong></p><p>As with any other injectable medicinal products, Irinotecan Jazeera solution must be prepared aseptically (see section 6.3).</p><p>&nbsp;</p><p>If any precipitate is observed in the vials or after dilution, the product should be discarded according to standard procedures for cytotoxic agents.</p><p>&nbsp;</p><p>Aseptically withdraw the required amount of Irinotecan Jazeera solution from the vial with a calibrated syringe and inject into a 250 ml polyethylene infusion bag or bottle containing either 0.9% sodium chloride solution or 5% dextrose solution. The infusion should then be thoroughly mixed by manual rotation.</p><p>&nbsp;</p><p><strong>Disposal:</strong></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22 December 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>